Complex antisense compounds and uses thereof

Abstract

To provide techniques for facilitating uptake and distribution of antisense compounds into other cell types, such as CNS tissue or muscle tissue.SOLUTION: The present disclosure provides half duplex compounds comprising a first oligomeric compound and a second, shorter, oligomeric compound, where the first oligomeric compound is complementary to a target nucleic acid and the second oligomeric compound is complementary to the first oligomeric compound. In certain embodiments, the compounds disclosed herein are useful for modulating the expression of extra-hepatic target nucleic acids.SELECTED DRAWING: None

Description

[Technical Field]

[0001] Sequence Listing This application is filed with an electronic Sequence Listing, which is provided as a file entitled CORE0145WOSEQ_ST25.txt, created on December 13, 2018, and measuring 24 Kb in size. The information in the electronic format of the Sequence Listing is incorporated herein by reference in its entirety. [Background technology]

[0002] The principle behind antisense technology is that antisense compounds hybridize with target nucleic acids and modulate the amount, activity, and / or function of the target nucleic acid. In certain cases, antisense compounds cause changes in the transcription or translation of the target. Such expression modulation can be achieved, for example, by degrading or inhibiting the target mRNA based on occupancy. One example of modulating target RNA function through degradation is the inhibition of RNase A upon hybridization of the target RNA with a DNA-like antisense compound. The H-mediated degradation of target RNAs is another example of regulating gene expression through target degradation. RNA interference (RNAi) refers to antisense-mediated gene silencing via a mechanism that utilizes the RNA-induced silencing complex (RISC). Another example of regulating target RNA function is the occupancy-based mechanism utilized by microRNAs in nature. MicroRNAs are small non-coding RNAs that regulate the expression of protein-coding RNAs. Binding of antisense compounds to microRNAs prevents the binding of the microRNA to its target messenger RNA, thereby interfering with microRNA function. MicroRNA mimics can enhance natural microRNA function. Certain antisense compounds alter pre-mRNA splicing. Regardless of the specific mechanism, sequence specificity makes antisense compounds attractive as a tool for target validation and gene functionalization, as well as therapeutic agents for selectively modulating the expression of genes involved in disease pathogenesis.

[0003] Antisense technology is an effective means of modulating the expression of one or more specific gene products and may therefore prove uniquely useful in numerous therapeutic, diagnostic, and research applications. Chemically modified nucleosides may be incorporated into antisense compounds to enhance one or more properties, such as nuclease resistance, pharmacokinetics, or affinity for target nucleic acids. In 1998, the antisense compound Vitravene® (fomilirsen; developed by Isis Pharmaceuticals Inc., Carlsbad, CA) was the first antisense drug to receive marketing approval from the US Food and Drug Administration (FDA) and is currently used to treat cytomegalovirus (CMV)-induced retinitis in AIDS patients. In another example, KYNAMRO™, an antisense oligonucleotide targeted to apoB, has been approved by the US Food and Drug Administration (FDA) as a lipid-lowering agent in patients with homozygous familial hypercholesterolemia (HoFH) and as an adjunct to a diet to lower low-density lipoprotein cholesterol (LDL-C), apoB, total cholesterol (TC), and non-high-density lipoprotein cholesterol (non-HDL-C).

[0004] New chemical modifications have improved the potency and efficacy of antisense compounds, demonstrating the potential for oral delivery and further enhancing subcutaneous administration, reducing the potential for side effects and improving patient convenience. Chemical modifications that increase the potency of antisense compounds allow for the administration of lower doses, thereby reducing the potential for toxicity and the overall cost of treatment. The cost of antisense compounds is reduced. Modifications that increase resistance to degradation allow for slower clearance from the body, allowing for less frequent administration. Different chemical modifications can be combined into a single compound to further optimize the efficacy of the compound. Previously, antisense compounds, such as modified oligonucleotides, have shown good uptake and function in liver tissue. However, there remains a need to enhance the uptake and distribution of antisense compounds into other cell types, such as CNS tissue or muscle tissue. Summary of the Invention

[0005] Oligomeric compounds typically show good distribution in the liver after being administered to a subject.However, in certain embodiments, there is a need to deliver oligomeric compounds to other tissues in a subject.For example, there is a need to deliver oligomeric compounds to one or more extrahepatic tissues, such as CNS tissue or muscle tissue.There is also a need to deliver oligomeric compounds to systemic delivery to regulate CNS target, for example, systemically delivered oligomeric compounds can pass through the blood-brain barrier and regulate the nucleic acid target of CNS.

[0006] The present disclosure provides half-duplex oligomeric compounds. The half-duplex oligomeric compounds comprise a first modified oligonucleotide and a second modified oligonucleotide, wherein the first modified oligonucleotide has 14 to 30 linked nucleosides and a nucleobase sequence complementary to the nucleobase sequence of the second oligomeric compound and a nucleic acid target, and the second modified oligonucleotide has 6 to 12 linked nucleosides. In certain embodiments, these half-duplex oligomeric compounds have one or more improved properties compared to the first modified oligonucleotide alone or the second modified oligonucleotide alone. One type of improved property is an improved safety profile. For example, half-duplexes may be much better tolerated than the first modified oligonucleotide alone or the second modified oligonucleotide alone. Another type of improved property is improved uptake in specific cell types. In certain embodiments, half-duplexes exhibit enhanced uptake and / or activity in muscle tissue. In certain embodiments, half-duplexes exhibit enhanced uptake and / or activity in the CNS. In certain embodiments, the half-duplex can cross the blood-brain barrier to a greater extent than the single-stranded versions of either the first modified oligonucleotide alone or the second modified oligonucleotide alone. In certain embodiments, the systemically administered half-duplex can cross the blood-brain barrier to a greater extent than the single-stranded versions of either the first modified oligonucleotide alone or the second modified oligonucleotide alone. In certain embodiments, the systemically administered half-duplex can modulate target nucleic acids in CNS tissue. In certain embodiments, the tissue is the striatum. In certain embodiments, the tissue is the spinal cord. In certain embodiments, the tissue is the cerebellum. In certain embodiments, the tissue is the cortex.

[0007] In certain embodiments, the second modified oligonucleotide of the half-duplex comprises a linking group. In certain embodiments, the linking group enhances uptake and / or activity in extrahepatic tissue. In certain embodiments, the linking group enhances uptake and / or activity in muscle tissue or CNS tissue.

[0008] In certain embodiments, the present disclosure provides methods for modulating the amount or activity of a target nucleic acid in extrahepatic tissues and / or cell types by contacting the cells with a hemiduplex. In certain such embodiments, the present disclosure provides methods for treating diseases in which modulating the amount or activity of a target nucleic acid in the liver alone is not sufficient to provide a therapeutic benefit. For example, the present disclosure provides methods for modulating the amount or activity of a target nucleic acid in the CNS. The present disclosure also provides methods for modulating the amount or activity of a target nucleic acid in muscle tissue.

[0009] The present disclosure provides the following non-limiting embodiments.

[0010] Embodiment 1. A compound comprising a first oligomeric compound and a second oligomeric compound, wherein the first oligomeric compound comprises a first modified oligonucleotide consisting of 14 to 30 linked nucleosides and has a nucleobase sequence complementary to a nucleobase sequence of the second oligomeric compound and a nucleic acid target, and the second oligomeric compound comprises a second modified oligonucleotide consisting of 6 to 12 linked nucleosides.

[0011] Embodiment 2. The compound of embodiment 1, wherein the first modified oligonucleotide has a nucleobase sequence that is at least 80% complementary to the nucleobase sequence of the target nucleic acid as measured across the entire nucleobase sequence of the first modified oligonucleotide.

[0012] Embodiment 3. The compound of embodiment 1, wherein the first modified oligonucleotide has a nucleobase sequence that is at least 90% complementary to the nucleobase sequence of the target nucleic acid as measured across the entire nucleobase sequence of the first modified oligonucleotide.

[0013] Embodiment 4. The compound of embodiment 1, wherein the first modified oligonucleotide has a nucleobase sequence that is 100% complementary to the nucleobase sequence of the target nucleic acid when measured across the entire nucleobase sequence of the first modified oligonucleotide.

[0014] Embodiment 5. The compound of any of embodiments 1-4, wherein the first modified oligonucleotide has at least 8 contiguous nucleobases of SEQ ID NO:2.

[0015] Embodiment 6. The compound of any of embodiments 1-4, wherein the first modified oligonucleotide has at least 9 contiguous nucleobases of SEQ ID NO:2.

[0016] Embodiment 7. The compound of any of embodiments 1-4, wherein the first modified oligonucleotide has at least 10 contiguous nucleobases of SEQ ID NO:2.

[0017] Embodiment 8. The compound of any of embodiments 1-4, wherein the first modified oligonucleotide has at least 11 contiguous nucleobases of SEQ ID NO:2.

[0018] Embodiment 9. The compound of any of embodiments 1-4, wherein the first modified oligonucleotide has at least 12 contiguous nucleobases of SEQ ID NO:2.

[0019] Embodiment 10. The compound of any of embodiments 1-9, wherein the first modified oligonucleotide comprises at least one modified nucleoside.

[0020] Embodiment 11. The compound of embodiment 10, wherein the first modified oligonucleotide comprises at least one modified nucleoside comprising a modified sugar moiety.

[0021] Embodiment 12. The compound of embodiment 11, wherein the first modified oligonucleotide comprises at least one modified nucleoside comprising a bicyclic sugar moiety.

[0022] Embodiment 13. The compound of embodiment 12, wherein the first modified oligonucleotide comprises at least one modified nucleoside comprising a bicyclic sugar moiety having a 2'-4' bridge, wherein the 2'-4' bridge is chosen from -O-CH2- and -O-CH(CH3)-.

[0023] Embodiment 14. The compound of embodiment 12, wherein the first modified oligonucleotide comprises at least one modified nucleoside comprising a bicyclic sugar moiety selected from among cEt or LNA.

[0024] Embodiment 15. The compound of embodiment 12, wherein the first modified oligonucleotide comprises at least one modified nucleoside comprising a cEt bicyclic sugar moiety.

[0025] Embodiment 16. The compound of any of embodiments 10-15, wherein the first modified oligonucleotide comprises at least one modified nucleoside comprising a modified non-bicyclic sugar moiety.

[0026] Embodiment 17. The compound of embodiment 16, wherein the first modified oligonucleotide comprises at least one modified nucleoside comprising a non-bicyclic sugar moiety comprising 2'-MOE or 2'-OMe.

[0027] Embodiment 18. The compound of embodiment 16, wherein the first modified oligonucleotide comprises at least one modified nucleoside, including a 2'-MOE modified nucleoside.

[0028] Embodiment 19. The compound of any of embodiments 10-18, wherein the first modified oligonucleotide comprises at least one modified nucleoside that comprises a sugar surrogate.

[0029] Embodiment 20. The compound of embodiment 19, wherein the first modified oligonucleotide comprises at least one modified nucleoside comprising a sugar surrogate selected from morpholino, PNA, F-HNA, THP, or modified THP.

[0030] Embodiment 21. The first modified oligonucleotide comprises: a 5'-region consisting of 1 to 5 linked 5'-nucleosides; a central region consisting of 6 to 10 linked central region nucleosides, and A 3'-region consisting of 1 to 5 linked 3'-nucleosides wherein each of the 5'-region nucleosides and each of the 3'-region comprises a modified sugar moiety, and each of the central region nucleosides comprises an unmodified DNA sugar moiety.

[0031] Embodiment 22. The first modified oligonucleotide comprises: a 5'-region consisting of 5 linked 5'-nucleosides; a central region consisting of 10 linked central region nucleosides, and A 3'-region consisting of five linked 3'-nucleosides wherein each of the 5'-region nucleosides and each of the 3'-region comprises a modified sugar moiety, and each of the central region nucleosides comprises an unmodified DNA sugar moiety.

[0032] Embodiment 23. The first modified oligonucleotide comprises: a 5'-region consisting of three linked 5'-nucleosides, a central region consisting of 10 linked central region nucleosides, and A 3'-region consisting of three linked 3'-nucleosides wherein each of the 5'-region nucleosides and each of the 3'-region comprises a modified sugar moiety, and each of the central region nucleosides comprises an unmodified DNA sugar moiety.

[0033] Embodiment 24. The compound of any of embodiments 1-11 or 16-18, wherein each nucleoside of the first modified oligonucleotide comprises a non-bicyclic sugar moiety that comprises a 2'-MOE.

[0034] Embodiment 25. The compound of any of embodiments 1-11 or 16-18, wherein each nucleoside of the first modified oligonucleotide comprises a non-bicyclic sugar moiety that includes 2'-OMe. Compound.

[0035] Embodiment 26. The compound of any of embodiments 1-11 or 16-20, wherein each nucleoside of the first modified oligonucleotide comprises a sugar surrogate selected from morpholino, PNA, F-HNA, THP, or modified THP.

[0036] Embodiment 27. The compound of any of embodiments 1-20 or 24-26, wherein the first modified oligonucleotide consists of 14 to 22 linked nucleosides.

[0037] Embodiment 28. The compound of any of embodiments 1-20 or 24-26, wherein the first modified oligonucleotide consists of 14 to 20 linked nucleosides.

[0038] Embodiment 29. The compound of any of embodiments 1-20 or 24-26, wherein the first modified oligonucleotide consists of 16 to 20 linked nucleosides.

[0039] Embodiment 30. The compound of any of embodiments 1-20 or 24-26, wherein the first modified oligonucleotide consists of 16 to 18 linked nucleosides.

[0040] Embodiment 31. The compound of any of embodiments 1-20 or 24-26, wherein the first modified oligonucleotide consists of 16 linked nucleosides.

[0041] Embodiment 32. The compound of any of embodiments 1-22 or 24-26, wherein the first modified oligonucleotide consists of 20 linked nucleosides.

[0042] Embodiment 33. The compound of any of embodiments 1-32, wherein the first modified oligonucleotide comprises at least one modified internucleoside linkage.

[0043] Embodiment 34. The compound of embodiment 33, wherein each internucleoside linkage of said first modified oligonucleotide is a modified internucleoside linkage.

[0044] Embodiment 35. The compound of embodiment 33 or 34, wherein at least one internucleoside linkage of said first oligonucleotide is a phosphorothioate internucleoside linkage.

[0045] Embodiment 36. The compound of any of embodiments 1-33, wherein the first modified oligonucleotide comprises at least one unmodified phosphodiester internucleoside linkage.

[0046] Embodiment 37. The compound of any of embodiments 1-36, wherein each internucleoside linkage of the first oligonucleotide is either an unmodified phosphodiester internucleoside linkage or a phosphorothioate internucleoside linkage.

[0047] Embodiment 38. The compound of embodiment 34, wherein each internucleoside linkage of said first oligonucleotide is a phosphorothioate internucleoside linkage.

[0048] Embodiment 39. The compound of embodiments 1-38, wherein the second modified oligonucleotide is at least 75% complementary to the first modified oligonucleotide over the length of the second modified nucleotide.

[0049] Embodiment 40. The second modified oligonucleotide is at least 80% complementary to the first modified oligonucleotide over the length of the second modified nucleotide. The compound according to any one of embodiments 1 to 38.

[0050] Embodiment 41. The compound of embodiments 1-38, wherein the second modified oligonucleotide is at least 90% complementary to the first modified oligonucleotide over the length of the second modified nucleotide.

[0051] Embodiment 42. The compound of embodiments 1-38, wherein the second modified oligonucleotide is at least 100% complementary to the first modified oligonucleotide over the length of the second modified nucleotide.

[0052] Embodiment 43. The compound of any of embodiment 42, wherein the second modified oligonucleotide has at least 6 contiguous nucleobases of SEQ ID NO:4.

[0053] Embodiment 44. The compound of any of embodiment 42, wherein the second modified oligonucleotide has at least 6 contiguous nucleobases of SEQ ID NO:5.

[0054] Embodiment 45. The compound of any of embodiments 1-44, wherein the second modified oligonucleotide comprises at least one modified nucleoside.

[0055] Embodiment 46. The compound of embodiment 45, wherein the second modified oligonucleotide comprises at least one modified nucleoside comprising a modified sugar moiety.

[0056] Embodiment 47. The compound of embodiment 46, wherein the second modified oligonucleotide comprises at least one modified nucleoside comprising a bicyclic sugar moiety.

[0057] Embodiment 48. The compound of embodiment 47, wherein the second modified oligonucleotide comprises at least one modified nucleoside comprising a bicyclic sugar moiety having a 2'-4' bridge, wherein the 2'-4' bridge is chosen from -O-CH2- and -O-CH(CH3)-.

[0058] Embodiment 49. The compound of embodiment 48, wherein the second modified oligonucleotide comprises at least one modified nucleoside comprising a bicyclic sugar moiety selected from among cEt or LNA.

[0059] Embodiment 50. The compound of embodiment 48, wherein the second modified oligonucleotide comprises at least one modified nucleoside comprising a cEt bicyclic sugar moiety.

[0060] Embodiment 51. The compound of any of embodiments 45-50, wherein the second modified oligonucleotide comprises at least one modified nucleoside comprising a modified non-bicyclic sugar moiety.

[0061] Embodiment 52. The compound of embodiment 51, wherein the second modified oligonucleotide comprises at least one modified nucleoside comprising a non-bicyclic sugar moiety comprising 2'-MOE or 2'-OMe.

[0062] Embodiment 53. The compound of any of embodiments 1-52, wherein the second modified oligonucleotide comprises at least one modified nucleoside that comprises a sugar surrogate.

[0063] Embodiment 54. The compound of embodiment 53, wherein the second modified oligonucleotide comprises at least one modified nucleoside comprising a sugar surrogate selected from morpholino, PNA, F-HNA, THP, or modified THP.

[0064] Embodiment 55. The second modified oligonucleotide comprises: a 5'-region consisting of 2 to 4 linked 5'-nucleosides; a central region consisting of 2 to 4 linked central region nucleosides, and A 3'-region consisting of 2 to 4 linked 3'-nucleosides wherein each of the 5'-region nucleosides and each of the 3'-region comprises a modified sugar moiety, and each of the central region nucleosides comprises an unmodified DNA sugar moiety.

[0065] Embodiment 56. The second modified oligonucleotide comprises: a 5'-region consisting of two linked 5'-nucleosides, a central region consisting of four linked central region nucleosides, and A 3'-region consisting of two linked 3'-nucleosides wherein each of the 5'-region nucleosides and each of the 3'-region comprises a modified sugar moiety, and each of the central region nucleosides comprises an unmodified DNA sugar moiety.

[0066] Embodiment 57. The second modified oligonucleotide comprises: a 5'-region consisting of four linked 5'-nucleosides; a central region consisting of two linked central region nucleosides, and A 3'-region consisting of three linked 3'-nucleosides wherein each of the 5'-region nucleosides and each of the 3'-region comprises a modified sugar moiety, and each of the central region nucleosides comprises an unmodified DNA sugar moiety.

[0067] Embodiment 58. The compound of embodiments 1-38 or embodiments 51-57, wherein each nucleoside of the second modified oligonucleotide comprises a non-bicyclic sugar moiety that comprises a 2'-MOE.

[0068] Embodiment 59. The compound of embodiments 1-38 or embodiments 51-57, wherein each nucleoside of the second modified oligonucleotide comprises a non-bicyclic sugar moiety that comprises 2'-OMe.

[0069] Embodiment 60. The compound of any of embodiments 1-38 or embodiments 51-57, wherein each nucleoside of the second modified oligonucleotide comprises a sugar surrogate selected from morpholino, PNA, F-HNA, THP, or modified THP.

[0070] Embodiment 61. The compound of any of embodiments 1-60, wherein the second modified oligonucleotide consists of 6 to 10 linked nucleosides.

[0071] Embodiment 62. The compound of any of embodiments 1-60, wherein the second modified oligonucleotide consists of 7 to 10 linked nucleosides.

[0072] Embodiment 63. The compound of any of embodiments 1-60, wherein the second modified oligonucleotide consists of 8 to 10 linked nucleosides.

[0073] Embodiment 64. The compound of any of embodiments 1-60, wherein the second modified oligonucleotide consists of 8 to 9 linked nucleosides.

[0074] Embodiment 65. The compound of any of embodiments 1-60, wherein the second modified oligonucleotide consists of 7 to 9 linked nucleosides.

[0075] Embodiment 66. The compound of any of embodiments 1-56, wherein the second modified oligonucleotide consists of 8 linked nucleosides.

[0076] Embodiment 67. The compound of any of embodiments 1-55 or 57, wherein the second modified oligonucleotide consists of 9 linked nucleosides.

[0077] Embodiment 68. The compound of any of embodiments 1-67, wherein the second modified oligonucleotide comprises at least one modified internucleoside linkage.

[0078] Embodiment 69. The compound of embodiment 68, wherein each internucleoside linkage of the second modified oligonucleotide is either an unmodified phosphodiester internucleoside linkage or a phosphorothioate internucleoside linkage.

[0079] Embodiment 70. The compound of embodiment 68 or 69, wherein each nucleoside linkage of the second modified oligonucleotide is a phosphorothioate internucleoside linkage.

[0080] Embodiment 71. The compound of embodiment 69, wherein each nucleoside linkage of the second modified oligonucleotide is an unmodified phosphodiester internucleoside linkage.

[0081] Embodiment 72. The compound of any of embodiments 1-71, wherein the first modified oligonucleotide or the second modified oligonucleotide comprises at least one modified nucleobase.

[0082] Embodiment 73. The compound of embodiment 72, wherein the modified nucleobase is 5'-Me cytosine.

[0083] Embodiment 74. The compound of embodiment 72, wherein each nucleobase of each modified oligonucleotide is an unmodified nucleobase or is a 5'-Me cytosine.

[0084] Embodiment 75. The compound of any of embodiments 1-74, wherein the 3'-most nucleobase of the second modified oligonucleotide is complementary to the 5'-most nucleobase of the first modified oligonucleotide.

[0085] Embodiment 76. The compound of any of embodiments 1-75, wherein the linking group is covalently attached to the first modified oligonucleotide.

[0086] Embodiment 77. The compound of any of embodiments 1-75, wherein the linking group is covalently attached to the second modified oligonucleotide.

[0087] Embodiment 78. The compound of any of embodiments 1-75, wherein the linking group is covalently attached to the 3' end of the first modified oligonucleotide.

[0088] Embodiment 79. The compound of any of embodiments 1-75, wherein the linking group is covalently attached to the 5' end of the first modified oligonucleotide.

[0089] Embodiment 80. The compound of any of embodiments 1-75, wherein the linking group is covalently attached to the 3' end of the second modified oligonucleotide.

[0090] Embodiment 81. The linking group is covalently attached to the 5' end of the second modified oligonucleotide. 76. The compound of any of embodiments 1-75, wherein the compound is attached by

[0091] Embodiment 82. The compound of any of embodiments 1-81, wherein the linking group comprises a coupling linker.

[0092] Embodiment 83. The compound of any of embodiments 1-82, wherein the linking group comprises a linking moiety.

[0093] Embodiment 84. The compound of any of embodiments 1-83, wherein the linking group consists of a connecting linker and a linking moiety.

[0094] Embodiment 85. The compound of any of embodiments 1-84, wherein the binding moiety is a lipid.

[0095] Embodiment 86. The compound of any of embodiments 1-84, wherein the binding moiety is cholesterol.

[0096] Embodiment 87. The compound of any of embodiments 78-86, wherein the attachment linker is TCA.

[0097] Embodiment 88. The compound of any of embodiments 78-86, wherein the attachment linker is TEG.

[0098] Embodiment 89. The compound of any of embodiments 78-86, wherein the attachment linker is hexylamino.

[0099] Embodiment 90. The compound of any of embodiments 1-89, wherein the compound exists predominantly as a duplex at or below 57°C.

[0100] Embodiment 91. The compound of any of embodiments 1-89, wherein the compound exists predominantly as a duplex at or below 47°C.

[0101] Embodiment 92. The compound of any of embodiments 1-89, wherein the compound exists predominantly as a duplex at 37°C.

[0102] Embodiment 93. A pharmaceutical composition comprising a compound of any one of embodiments 1 to 92 and a pharmaceutically acceptable carrier or diluent.

[0103] Embodiment 94. A pharmaceutical composition comprising a compound of any one of embodiments 1 to 92 and a pharmaceutically acceptable carrier or diluent.

[0104] Embodiment 95. A method comprising administering to an animal a compound or pharmaceutical composition according to any one of embodiments 1 to 94.

[0105] Embodiment 96. The method of embodiment 95, wherein the compound or pharmaceutical composition of any of embodiments 1-94 is administered systemically.

[0106] Embodiment 97. A method of treating a disease associated with an extrahepatic nucleic acid target, comprising administering to an individual suffering from or at risk of developing said disease associated with an extrahepatic nucleic acid target a therapeutically effective amount of a compound or pharmaceutical composition according to any of embodiments 1 to 94, thereby improving or preventing the progression of the disease. treating said disease associated with said extrahepatic nucleic acid target.

[0107] Embodiment 98. The method of embodiment 97, wherein the extrahepatic nucleic acid target is a muscle target.

[0108] Embodiment 99. The method of embodiment 97, wherein the extrahepatic nucleic acid target is DMPK.

[0109]

[0033] Embodiment 100. The method of embodiment 97, wherein said extrahepatic nucleic acid target is a CNS target.

[0110] Embodiment 101. The method of any of embodiments 97-100, wherein the administration is systemic. DETAILED DESCRIPTION OF THE INVENTION

[0111] It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not limiting. As used herein, the use of the singular includes the plural unless specifically stated otherwise. As used herein, the use of "or" means "and / or" unless specifically stated otherwise. Furthermore, the use of the term "including" and other forms, such as "includes" and "included," is not limiting. Also, terms such as "element" or "component" encompass both elements and components comprising a single unit and elements and components comprising two or more subunits, unless specifically stated otherwise.

[0112] The section headings used herein are for organizational purposes only and should not be construed as limiting the subject matter described. All materials or portions of materials cited in this application, including but not limited to patents, patent applications, articles, books, and treatises, are expressly incorporated herein by reference in their entirety as well as any portion of the material discussed herein.

[0113] definition Unless otherwise defined, the nomenclature used in connection with, and the procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those commonly used and well known in the art. Where permitted, all patents, applications, published applications, and other publications and other materials mentioned throughout this disclosure are incorporated herein by reference in their entirety.

[0114] Unless otherwise stated, the following terms have the following meanings:

[0115] "2'-deoxynucleoside" means a nucleoside containing a 2'-H(H) furanosyl sugar moiety found in naturally occurring deoxyribonucleic acid (DNA). In certain embodiments, 2'-deoxynucleosides may contain modified nucleobases or may contain RNA nucleobases (uracil).

[0116] "2'-substituted nucleoside" or "2-modified nucleoside" means a nucleoside that includes a 2'-substituted or 2'-modified sugar moiety. As used herein, "2'-substituted" or "2-modified" in reference to a sugar moiety means a sugar moiety that includes at least one 2'-substituent group other than H or OH.

[0117] "Antisense activity" refers to any detectable and / or measurable change that results from hybridization of an antisense compound to its target nucleic acid. In certain embodiments, antisense activity refers to a change in the level of a target nucleic acid or a protein encoded by such a target nucleic acid, compared to the level of the target nucleic acid or target protein in the absence of the antisense compound. In certain embodiments, antisense activity is a decrease in the amount or expression of a protein. In certain embodiments, antisense activity is a change in the splicing of a pre-mRNA nucleic acid target. In certain embodiments, antisense activity is an increase in the amount or expression of a target nucleic acid or a protein encoded by such a target nucleic acid compared to the target nucleic acid or target protein level in the absence of the antisense compound.

[0118] By "antisense compound" is meant a compound comprising an antisense oligonucleotide and, optionally, one or more additional features, such as a linking group or a terminal group.

[0119] By "antisense oligonucleotide" is meant an oligonucleotide that (1) has a nucleobase sequence that is at least partially complementary to a target nucleic acid, and (2) is capable of producing antisense activity in a cell or animal.

[0120] "Ameliorate," in the context of treatment, means that at least one symptom is better than it would be if the same symptom were not treated. In certain embodiments, improvement is a decrease in the severity or frequency of a symptom, or a delay in the onset of a symptom or a slowing of the progression of the severity or frequency of a symptom.

[0121] "Bicyclic nucleoside" or "BNA" refers to a nucleoside containing a bicyclic sugar moiety. As used herein, "bicyclic sugar" or "bicyclic sugar moiety" refers to a modified sugar moiety containing two rings, where the second ring is formed via a bridge connecting two atoms of the first ring to form a bicyclic structure. In certain embodiments, the first ring of the bicyclic sugar moiety is a furanosyl moiety. In certain embodiments, the bicyclic sugar moiety does not contain a furanosyl moiety.

[0122] "Branching group" means a group of atoms having at least three positions capable of forming covalent bonds with at least three groups. In certain embodiments, the branching group provides multiple reactive sites for connecting the tethered ligand and the oligonucleotide via a bond linker and / or cleavable moiety.

[0123] By "cell-targeting moiety" is meant a binding group or portion of a binding group that is capable of binding to a specific cell type or specific cell types.

[0124] By "cleavable moiety" is meant an atomic bond or group that is cleaved under physiological conditions, eg, inside a cell, animal, or human.

[0125] The term "complementary" in the context of an oligonucleotide means that when the nucleobase sequence of the oligonucleotide and the nucleobase sequence of another nucleic acid are aligned in opposite directions, at least 70% of the nucleobases of the oligonucleotide, or one or more regions thereof, can hydrogen bond with the nucleobases of the other nucleic acid, or one or more regions thereof. Complementary nucleobases refer to nucleobases that can form hydrogen bonds with each other. Complementary nucleobase pairs include adenine (A) and thymine (T), adenine (A) and uracil (U), cytosine (C) and guanine (G), 5-methylcytosine ( ... m Examples of complementary bases include, but are not limited to, guanine (G) and guanine (C), unless otherwise specified. Complementary oligonucleotides and / or nucleic acids do not necessarily have to be nucleobase-complementary at every nucleoside. Rather, some mismatches are permitted. As used herein, "fully complementary" or "100% complementary" in reference to an oligonucleotide means that such oligonucleotide is complementary to another oligonucleotide or nucleic acid at every nucleoside of the oligonucleotide.

[0126] "Linking group" means a group of atoms that is directly or indirectly attached to an oligonucleotide. Linking groups include binding moieties and attachment linkers that attach such binding moieties to the oligonucleotide.

[0127] By "attached linker" is meant a group of atoms that includes at least one bond connecting a binding moiety to an oligonucleotide.

[0128] "Linking moiety" means a group of atoms that is attached to an oligonucleotide via an attachment linker.

[0129] In oligonucleotides, "contiguous" refers to nucleosides, nucleobases, sugar moieties, or internucleoside linkages that are immediately adjacent to each other. For example, "contiguous nucleobases" means nucleobases that are immediately adjacent to each other in sequence.

[0130] "Duplex" means two oligomeric compounds that are paired. In certain embodiments, the two oligomeric compounds are paired through hybridization of complementary nucleobases.

[0131] By "extrahepatic cell type" is meant a cell type that is not a hepatic cell.

[0132] "Extrahepatic nucleic acid target" refers to a target nucleic acid that is expressed in tissues other than the liver. In certain embodiments, the extrahepatic nucleic acid target is not expressed in the liver or is not expressed at significant levels in the liver. In certain embodiments, the extrahepatic nucleic acid target is expressed outside the liver and also within the liver.

[0133] "Extrahepatic tissue" means tissue other than the liver.

[0134] "Fully modified" in reference to a modified oligonucleotide refers to a modified oligonucleotide in which each sugar moiety is modified. "Uniformly modified" in reference to a modified oligonucleotide refers to a fully modified oligonucleotide in which each sugar moiety is the same. For example, the nucleosides of a uniformly modified oligonucleotide may each have a 2'-MOE modification but have different nucleobase modifications, and the internucleoside linkages may be different.

[0135] "Gapmer" means an antisense oligonucleotide containing an internal region having multiple nucleosides that support cleavage by RNase H, flanked by external regions having one or more nucleosides, wherein the nucleosides contained in the internal region are chemically distinct from the nucleoside or nucleosides contained in the external regions. The internal regions may be referred to as the "gap" and the external regions may be referred to as the "wings."

[0136] "Hybridization" refers to the pairing or annealing of complementary oligonucleotides and / or nucleic acids. While not limited to a particular mechanism, the most common mechanism of hybridization involves hydrogen bonding, which can be Watson-Crick, Hoogsteen, or reversed Hoogsteen hydrogen bonding between complementary nucleobases.

[0137] "Inhibiting expression or activity" refers to a reduction or blocking of expression or activity compared to expression or activity in an untreated or control sample, and does not necessarily indicate a complete absence of expression or activity.

[0138] "Internucleoside linkage" means a group or bond that forms a covalent bond between adjacent nucleosides in an oligonucleotide. As used herein, "modified nucleosides" refers to "Internucleoside linkage" refers to any internucleoside linkage other than a naturally occurring phosphodiester internucleoside linkage. Non-phosphate linkages are referred to herein as modified internucleoside linkages. "Phosphorothioate linkage" refers to a modified phosphate linkage in which one of the non-bridging oxygen atoms is replaced with a sulfur atom. A phosphorothioate internucleoside linkage is a modified internucleoside linkage.

[0139] "Linker nucleoside" means a nucleoside that directly or indirectly connects an oligonucleotide to a linking moiety. The linker nucleoside is located within the linker of an oligomeric compound. The linker nucleoside is not considered part of the oligonucleotide portion of the oligomeric compound, even if it is adjacent to the oligonucleotide.

[0140] The terms "lipophilic group" or "lipophilicity," when used in reference to a chemical group, refer to a group of atoms that is more soluble in lipids or organic solvents than in water and / or has a greater affinity for lipids than for water. In certain embodiments, the lipophilic group comprises a lipid. As used herein, "lipid" refers to a molecule that is insoluble in water or that is less soluble in water than in organic solvents. In certain embodiments, the compounds of the present invention comprise a lipid selected from saturated or unsaturated fatty acids, steroids, fat-soluble vitamins, phospholipids, sphingolipids, hydrocarbons, monoglycerides, diglycerides, and triglycerides, and synthetic derivatives thereof.

[0141] By "non-bicyclic modified sugar" or "non-bicyclic modified sugar moiety" is meant a modified sugar moiety that includes a modification, e.g., a substituent, that does not form a bridge between two atoms of the sugar to form a second ring.

[0142] "Linked nucleosides" are nucleosides that are joined in contiguous sequence (ie, there are no additional nucleosides between the linked nucleosides).

[0143] "Mismatch" or "non-complementary" refers to a mismatch between the first and second oligomeric compounds when the first and second oligomeric compounds are aligned. One It means that the nucleobases are not complementary to the corresponding nucleobases of the second oligonucleotide or the target nucleic acid.

[0144] "MOE" means methoxyethyl. "2'-MOE" means an -OCH2CH2OCH3 group at the 2' position of the furanosyl ring.

[0145] "Motif" means the pattern of unmodified and / or modified sugar moieties, nucleobases, and / or internucleoside linkages in an oligonucleotide.

[0146] A "multi-tissue disease or condition" refers to a disease or condition that affects or is caused by more than one tissue. In treating a multi-tissue disease or condition, it is desirable to affect more than one tissue type. In certain embodiments, treatment of a disease or condition may be enhanced by treating the disease or condition in multiple tissues. For example, in certain embodiments, a disease or condition may manifest itself in liver tissue and muscle tissue. In certain embodiments, treating a disease or condition in liver tissue and muscle tissue is more effective than treating the disease in either liver tissue or muscle tissue.

[0147] "Naturally occurring" means found in nature.

[0148] "Nucleobase" means an unmodified nucleobase or a modified nucleobase. As used herein, an "unmodified nucleobase" is adenine (A), thymine (T), cytosine (C), uracil (U), and guanine (G). As used herein, a "modified nucleobase" is an unmodified A, T, C, U, or G capable of pairing with at least one unmodified nucleobase. A universal base is a modified nucleobase that can pair with any one of the five unmodified nucleobases. As used herein, "nucleobase sequence" refers to the order of consecutive nucleobases in a nucleic acid or oligonucleotide, independent of any modification of the sugar or internucleoside linkage.

[0149] "Nucleoside" refers to a compound comprising a nucleobase and a sugar moiety. The nucleobase and sugar moiety are each independently unmodified or modified. As used herein, "modified nucleoside" refers to a nucleoside comprising a modified nucleobase and / or a modified sugar moiety. Modified nucleosides include abasic nucleosides, which lack a nucleobase.

[0150] By "oligomeric compound" is meant a compound consisting of an oligonucleotide and, optionally, one or more additional features such as a linking group or a terminal group.

[0151] "Oligonucleotide" refers to a chain of linked nucleosides joined via internucleoside linkages, where each nucleoside and internucleoside linkage may be modified or unmodified. Unless otherwise specified, an oligonucleotide consists of 6 to 50 linked nucleosides. As used herein, "modified oligonucleotide" refers to an oligonucleotide in which at least one nucleoside or internucleoside linkage is modified. As used herein, "unmodified oligonucleotide" refers to an oligonucleotide that does not contain any nucleoside or internucleoside modifications.

[0152] "Pharmacologically acceptable carrier or diluent" means any substance suitable for use in administration to an animal. Certain such carriers enable the pharmaceutical compositions to be formulated as, for example, tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and lozenges for oral ingestion by a subject. In certain embodiments, the pharmaceutically acceptable carrier or diluent is sterile water, sterile saline, or a sterile buffer solution.

[0153] "Pharmacologically acceptable salt" means a physiologically and pharmacologically acceptable salt of a compound, such as an oligomeric compound, i.e., a salt that retains the desired biological activity of the parent compound and does not impart undesired toxicological effects thereto.

[0154] "Pharmaceutical composition" means a mixture of substances suitable for administration to a subject. For example, a pharmaceutical composition may comprise an antisense compound and a sterile aqueous solution. In certain embodiments, the pharmaceutical composition exhibits activity in a free uptake assay in a particular cell line.

[0155] "Phosphorus moiety" means a group of atoms that includes a phosphorus atom. In certain embodiments, the phosphorus moiety includes a monophosphate, diphosphate, or triphosphate, or a phosphorothioate.

[0156] "Prodrug" means a therapeutic agent in an ex vivo form that is converted into a different form inside the body or its cells. Typically, the conversion of a prodrug in the body is facilitated by the action of enzymes (e.g., endogenous or viral enzymes) or chemicals present in cells or tissues and / or by physiological conditions.

[0157] "RNAi compound" refers to an antisense compound that acts at least in part through RISC or Ago2 to regulate a target nucleic acid and / or a protein encoded by the target nucleic acid. RNAi compounds include, but are not limited to, double-stranded siRNA, single-stranded RNA (ssRNA), and microRNAs, such as microRNA mimics. In certain embodiments, an RNAi compound regulates the amount, activity, and / or splicing of a target nucleic acid. The term RNAi compound excludes antisense oligonucleotides that act through RNase H.

[0158] The term "single-stranded" in reference to an oligomeric compound refers to a compound that does not pair with a second oligomeric compound to form a duplex. The term "self-complementary" in reference to an oligonucleotide refers to an oligonucleotide that at least partially hybridizes with itself. A compound consisting of a single oligomeric compound where the oligonucleotide of the oligomeric compound is self-complementary is a single-stranded compound. A single-stranded antisense compound or oligomeric compound may be able to bind to a complementary oligomeric compound to form a duplex, in which case the compound is no longer considered single-stranded.

[0159] By "standard cellular assay" is meant the assay described in Example 1 and any reasonable variations thereof.

[0160] By "standard in vivo test" is meant the procedure described in Example 2 and any reasonable modifications thereof.

[0161] "Sugar moiety" refers to an unmodified sugar moiety or a modified sugar moiety. As used herein, "unmodified sugar moiety" refers to a 2'-OH(H) furanosyl moiety found in RNA (an "unmodified RNA sugar moiety") or a 2'-H(H) moiety found in DNA (an "unmodified DNA sugar moiety"). An unmodified sugar moiety has one hydrogen at each of the 1', 3', and 4' positions, one oxygen at the 3' position, and two hydrogens at the 5' position. As used herein, "modified sugar moiety" or "modified sugar" refers to a modified furanosyl sugar moiety or sugar surrogate. As used herein, a modified furanosyl sugar moiety refers to a furanosyl sugar containing a non-hydrogen substituent in place of at least one hydrogen of the unmodified sugar moiety. In certain embodiments, a modified furanosyl sugar moiety is a 2'-substituted sugar moiety. Such modified furanosyl sugar moieties include bicyclic and non-bicyclic sugars. As used herein, "sugar surrogate" refers to a modified sugar moiety having a moiety other than a furanosyl moiety that can link a nucleobase to another group, such as an internucleoside linkage, a linking group, or a terminal group, of an oligonucleotide. Modified nucleosides containing sugar surrogates can be incorporated at one or more positions within an oligonucleotide, and such oligonucleotides can hybridize to complementary oligomeric compounds or nucleic acids.

[0162] "Target nucleic acid" refers to a naturally occurring, identified nucleic acid. In certain embodiments, the target nucleic acid is an endogenous cellular nucleic acid, including, but not limited to, an RNA transcript, pre-mRNA, mRNA, or microRNA. In certain embodiments, the target nucleic acid is a viral nucleic acid. In certain embodiments, the target nucleic acid is the nucleic acid of interest that the antisense compound is designed to affect.

[0163] "Target region" means a portion of interest in a target nucleic acid to which an antisense compound is designed to hybridize.

[0164] "TCA motif" refers to three nucleosides whose nucleobase sequence is TCA (5' to 3'). Such nucleosides may have modified sugar moieties and / or modified internucleoside linkages. Unless otherwise specified, the nucleosides of a TCA motif contain unmodified 2'-deoxy sugar moieties and unmodified phosphodiester internucleoside linkages.

[0165] "Terminal group" means a chemical group or group of atoms that is covalently linked to the terminus of an oligonucleotide.

[0166] "CNS" means the central nervous system. The CNS includes the spinal cord and brain and cerebrospinal fluid.

[0167] "CNS tissue" means any cell or tissue of the CNS. CNS tissue includes the spinal cord and brain and cerebrospinal fluid.

[0168] "Cerebrospinal fluid" or "CSF" means the fluid that fills the spaces around the brain and spinal cord.

[0169] "Nervous system" means the network of nerve cells and nerve fibers that transmit nerve impulses between parts of the body. The nervous system includes glial cells and neurons. The nervous system includes the central nervous system and the peripheral nervous system.

[0170] "Brain target" refers to a nucleic acid transcript that has some desired therapeutic benefit by regulating the amount or activity of the nucleic acid transcript in brain tissue. For example, a given nucleic acid transcript may be expressed in multiple tissues, but when the amount or activity of the target nucleic acid is regulated in brain tissue, one or more therapeutic benefits are obtained.

[0171] "CNS target" refers to a nucleic acid transcript that has some desired therapeutic benefit from regulating the amount or activity of the nucleic acid transcript in CNS tissue. For example, a given nucleic acid transcript may be expressed in multiple tissues, but one or more therapeutic benefits may be obtained when the amount or activity of the target nucleic acid is regulated in CNS tissue.

[0172] "Muscle-targeted" refers to a nucleic acid transcript in which regulating the amount or activity of the nucleic acid transcript in muscle tissue provides some desired therapeutic benefit. Muscle tissue includes, but is not limited to, smooth muscle tissue and skeletal muscle tissue. For example, a given nucleic acid transcript may be expressed in multiple tissues, but one or more therapeutic benefits may be obtained when the amount or activity of the target nucleic acid is regulated in muscle tissue.

[0173] I. Specific Oligonucleotides In certain embodiments, the present disclosure provides compounds comprising a half-duplex, wherein the half-duplex comprises a first oligomeric compound and a second oligomeric compound. In certain embodiments, the first oligomeric compound or the second oligomeric compound comprises an oligonucleotide consisting of linked nucleosides. The oligonucleotide may be an unmodified oligonucleotide (RNA or DNA) or a modified oligonucleotide. The modified oligonucleotide, such as the first modified oligonucleotide or the second modified oligonucleotide, comprises at least one modification relative to unmodified RNA or DNA (i.e., comprises at least one modified nucleoside (comprising a modified sugar moiety and / or a modified nucleobase) and / or at least one modified internucleoside linkage).

[0174] A. Certain modified nucleosides A modified nucleoside comprises a modified sugar moiety, or a modified nucleobase, or both a modified sugar moiety and a modified nucleobase.

[0175] 1. Specific sugar moieties In certain embodiments, the modified sugar moiety is a non-bicyclic modified sugar moiety. In certain embodiments, the modified sugar moiety is a bicyclic or tricyclic sugar moiety. In certain embodiments, the modified sugar moiety is a sugar surrogate. Such sugar surrogates may contain one or more substitutions that correspond to substitutions in other types of modified sugar moieties.

[0176] In certain embodiments, the modified sugar moiety is a non-bicyclic modified sugar moiety comprising a furanosyl ring bearing one or more acyclic substituents, including, but not limited to, substituents at the 2', 4', and / or 5' positions. In certain embodiments, one or more of the non-bicyclic modified sugar moieties The above acyclic substituents are branched. Examples of suitable 2'-substituents for non-bicyclic modified sugar moieties include, but are not limited to, 2'-F, 2'-OCH3 ("OMe" or "O-methyl"), and 2'-O(CH2)2OCH3 ("MOE"). In certain embodiments, the 2'-substituent is halo, allyl, amino, azido, SH, CN, OCN, CF3, OCF3, O-C1-C 10 Alkoxy, O-C1-C 10 Substituted alkoxy, O-C-C 10 Alkyl, O-C1-C 10 Substituted alkyl, S-alkyl, N(R m )-alkyl, O-alkenyl, S-alkenyl, N(R m )-alkenyl, O-alkynyl, S-alkynyl, N(R m )-alkynyl, O-alkylenyl-O-alkyl, alkynyl, alkaryl, aralkyl, O-alkaryl, O-aralkyl, O(CH2)2SCH3, O(CH2)2ON(R m )(R n ) or OCH2C(=O)-N(R m )(R n ) (in that case, each R m and R n are independently H, an amino protecting group, or a substituted or unsubstituted C-C 10and 2'-substituents described in Cook et al., US 6,531,584, Cook et al., US 5,859,221, and Cook et al., US 6,005,087. Certain embodiments of these 2'-substituents may be further substituted with one or more substituents independently selected from hydroxyl, amino, alkoxy, carboxy, benzyl, phenyl, nitro(NO), thiol, thioalkoxy, thioalkyl, halogen, alkyl, aryl, alkenyl, and alkynyl. Examples of suitable 4'-substituents for non-bicyclic modified sugar moieties include alkoxy (e.g., methoxy), alkyl, and the 4'-substituents described in Manoharan et al. al., WO 2015 / 106128. Examples of suitable 5'-substituents for non-bicyclic modified sugar moieties include, but are not limited to, 5'-methyl (R or S), 5'-vinyl, and 5'-methoxy. In certain embodiments, the non-bicyclic modified sugar comprises two or more non-bridge-forming sugar substituents, such as a 2'-F-5'-methyl sugar moiety and the modified sugar moieties and modified nucleosides described in Migawa et al., WO 2008 / 101157 and Rajeev et al., US 2013 / 0203836.

[0177] In certain embodiments, the 2'-substituted nucleoside or 2'-non-bicyclic modified nucleoside is selected from the group consisting of F, NH, N, OCF, OCH, O(CH)NH, CHCH=CH, OCHCH=CH, OCHCHOCH, O(CH)SCH, O(CH)ON(R m )(R n ), O(CH2)2O(CH2)2N(CH3)2, and N-substituted acetamides (OCH2C(=O)-N(R m )(R n )) wherein each R m and R n are independently H, an amino protecting group, or a substituted or unsubstituted C-C 10 It is alkyl.

[0178] In certain embodiments, the 2'-substituted nucleoside or 2'-non-bicyclic modified nucleoside comprises a sugar moiety that includes a non-bridge-forming 2'-substituent selected from F, OCF3, OCH3, OCH2CHOCH3, O(CH2)2SCH3, O(CH2)2ON(CH3)2, O(CH2)2O(CH2)2N(CH3)2, and OCH2C(=O)-N(H)CH3 ("NMA").

[0179] In certain embodiments, the 2'-substituted nucleoside or 2'-non-bicyclic modified nucleoside comprises a sugar moiety that includes a non-bridge-forming 2'-substituent selected from F, OCH3, and OCH2CH2OCH3.

[0180] Nucleosides containing modified sugar moieties, such as non-bicyclic modified sugar moieties, can be referred to by the position(s) of the substitution(s) on the sugar moiety of the nucleoside. For example, a nucleoside containing a 2'-substituted or 2-modified sugar moiety is referred to as a 2'-substituted nucleoside or 2-modified nucleoside.

[0181] Certain modified sugar moieties include a bridge-forming sugar substituent that forms a second ring to give a bicyclic sugar moiety. In certain such embodiments, the bicyclic sugar moiety includes a bridge between the 4' and 2' positions of the furanose ring atoms. Examples of such sugar substituents that form a 4' to 2' bridge include 4'-CH2-2', 4'-(CH2)2-2', 4'-(CH2)3-2', 4'-CH2-O-2' ("LNA"), 4'-CH2-S-2', 4'-(CH2)2-O-2' ("ENA"), 4'-CH(CH3)-O-2' (referred to as "constrained ethyl" or "cEt" when in the S configuration), 4'-CH2-O-CH2-2', 4'-CH2-N(R)-2', 4'-CH(CHOCH3)-O-2' ("constrained MOE" or "cMOE") and analogs thereof (e.g., Seth et al., US 7,399,845; Bhat et al., US 7,569,686; Swayze et al., US 7,569,686). al., US 7,741,457, and Swayze et al., US 8,022,193), 4'-C(CH3)(CH3)-O-2' and analogs thereof (see, e.g., Seth et al., US 8,278,283), 4'-CH2-N(OCH3)-2' and analogs thereof (see, e.g., Prakash et al., US 8,278,425), 4'-CH2-ON(CH3)-2' (see, e.g., Allerson et al., US 7,696,345, and Allerson et al., US 8,124,745), 4'-CH2-C(H)(CH3)-2' (see, e.g., Zhou, et al., US 7,696,345, and Allerson et al., US 8,124,745), al., J. Org. Chem., 2009, 74, 118-134), 4'-CH2-C(=CH2)-2' and analogs thereof (see, e.g., Seth et al., U.S. Pat. No. 8,278,426), 4'-C(R a R b )-N(R)-O-2',4'-C(R a R b )-ON(R)-2', 4'-CH2-ON(R)-2', and 4'-CH2-N(R)-O-2' (wherein each R, R a , and R b are independently H, a protecting group, or C1-C 12alkyl) (see, for example, Imanishi et al., US Pat. No. 7,427,672).

[0182] In certain embodiments, such 4' to 2' bridges are independently -[C(R a )(R b )] n -, -[C(R a )(R b )] n -O-, -C(R a )=C(R b )-, -C(R a )=N-, -C(=NR a )-, -C(=O)-, -C(=S)-, -O-, -Si(R a )2-, -S(=O) x - and -N(R a )-, where: x is 0, 1, or 2, n is 1, 2, 3, or 4; R a and R b are independently H, a protecting group, hydroxyl, C1-C 12 Alkyl, substituted C1-C 12 Alkyl, C2-C 12 Alkenyl, substituted C2-C 12 Alkenyl, C2-C 12 Alkynyl, substituted C2-C 12 Alkynyl, C5-C 20 Aryl, substituted C5-C 20 is an aryl, heterocyclic radical, substituted heterocyclic radical, heteroaryl, substituted heteroaryl, C5-C7 cycloaliphatic radical, substituted C5-C7 cycloaliphatic radical, halogen, OJ1, NJ1J2, SJ1, N3, COOJ1, acyl (C(=O)-H), substituted acyl, CN, sulfonyl (S(=O)2-J1), or sulfoxyl (S(=O)-J1); and Each J1 and J2 is independently H, C1-C 12 Alkyl, substituted C1-C 12 Alkyl, C2-C12 Alkenyl, substituted C2-C 12 Alkenyl, C2-C 12 Alkynyl, substituted C2-C 12 Alkynyl, C5-C 20 Aryl, substituted C5-C 20 Aryl, acyl (C(=O)-H), substituted acyl, heterocyclic radical, substituted heterocyclic radical, C1-C 12 Aminoalkyl, substituted C1-C 12 aminoalkyl, or a protecting group.

[0183] Additional bicyclic sugar moieties are known in the art, see, e.g., Freier et al., Nucleic Acids Research, 1997, 25(22), 44 29-4443, Albaek et al., J.Org.Chem.,2006,71,7731-7740, Singh et al.,Chem.Commun.,1998,4,455-456, Koshkin et al.,Tetrahedron,1998,54,3607-3630, Kumar et al. al.,Bioorg.Med.Chem.Lett.,1998,8,2219-2222, Singh et al.,J.Org.Chem.,1998,63,10035-10039, Srivastava et al.,J.Am.Chem.Soc.,20017,129,8362-8379, Wengel et al. a., US7,053,207, Imanishi et al. al.,US6,268,490, Imanishi et al.US6,770,748, Imanishi et al.,USRE44,779, Wengel et al.,US6,794,499, Wengel et al. al., US6,670,461, Wengel et al., US7,034,133, Wengel et al., US8,080,644, Wengel et al., US8,034,909, Wengel et al., US8,153,365, Wengel et al., US7,572,582, and Ramasamy et al. al.,US6,525,191, Torsten et al.,WO2004 / 106356, Wengel et al.,WO1999 / 014226, Seth et al.,WO2007 / 134181, Seth et al.,US7,547,684, Seth et al.,US7,666,854, Seth et al. al., US8,088,746, Seth et al. See, e.g., Allerson et al., US 7,750,131, Seth et al., US 8,030,467, Seth et al., US 8,268,980, Seth et al., US 8,546,556, Seth et al., US 8,530,640, Migawa et al., US 9,012,421, Seth et al., US 8,501,805, and U.S. Patent Publication Nos. US 2008 / 0039618 (Allerson et al.) and US 2015 / 0191727 (Migawa et al.).

[0184] In certain embodiments, bicyclic sugar moieties and nucleosides incorporating such bicyclic sugar moieties are further defined by their isomeric configuration, for example, LNA nucleosides (described herein) can be in either the α-L or β-D configuration. [ka] α-L-methyleneoxy (4'-CH2-O-2') or α-L-LNA bicyclic nucleosides have been incorporated into antisense oligonucleotides that exhibit antisense activity (Frieden et al., Nucleic Acids Research, 2003, 21, 6365-6372). In this specification, the general description of bicyclic nucleosides includes both isomeric configurations. In the exemplary embodiments of this specification, when the position of a specific bicyclic nucleoside (e.g., LNA or cEt) is identified, unless otherwise specified, they are in the β-D configuration.

[0185] In certain embodiments, the modified sugar moiety comprises one or more non-bridge-forming sugar substituents and one or more bridge-forming sugar substituents (eg, a 5'-substituted sugar and a 4'-2' bridged sugar).

[0186] In certain embodiments, the modified sugar moiety is a sugar surrogate. In certain such embodiments, an oxygen atom of the sugar moiety is replaced with, for example, a sulfur, carbon, or nitrogen atom. In certain such embodiments, such modified sugar moieties also include bridge-forming and / or non-bridge-forming substituents as described herein. For example, certain sugar surrogates include a 4'-sulfur atom as well as substitutions at the 2' position (see, e.g., Bhat et al., US 7,875,733 and Bhat et al., US 7,939,677) and / or 5' position.

[0187] In certain embodiments, the sugar surrogate comprises a ring having more than five atoms. For example, in certain embodiments, the sugar surrogate comprises a six-membered tetrahydropyran ("THP"). Such tetrahydropyrans may be further modified or substituted. Nucleosides containing such modified tetrahydropyrans include hexitol nucleic acid ("HNA"), anitol nucleic acid ("ANA"), mannitol nucleic acid ("MNA") (see, e.g., Leumann, CJ. Bioorg. & Med. Chem. 2002, 10, 841-854), fluoroHNA: [ka] ("F-HNA", see, e.g., Swayze et al., US 8,088,904, Swayze et al., US 8,440,803, Swayze et al., US 8,796,437, and Swayze et al., US 9,005,906; F-HNA may also be referred to as F-THP or 3'-fluorotetrahydropyran), and a compound of the formula: [ka] wherein, independently, for each of said modified THP nucleosides: Bx is a nucleobase moiety, T3 and T4 are each independently an internucleoside linking group linking a modified THP nucleoside to the remainder of the oligonucleotide, or one of T3 and T4 is an internucleoside linking group linking a modified THP nucleoside to the remainder of the oligonucleotide and the other of T3 and T4 is H, a hydroxyl protecting group, a linked linking group, or a 5' or 3' terminal group; q1, q2, q3, q4, q5, q6, and q7 are each independently H, C1-C6 alkyl, substituted C1-C6 alkyl, C2-C6 alkenyl, substituted C2-C6 alkenyl, C2-C6 alkynyl, or substituted C2-C6 alkynyl; Each of R1 and R2 is independently selected from hydrogen, halogen, substituted or unsubstituted alkoxy, NJ1J2, SJ1, N3, OC(=X)J1, OC(=X)NJ1J2, NJ3C(=X)NJ1J2, and CN, where X is O, S, or NJ1; J1, J2, and J3 are independently H or C1-C6 alkyl. Nucleosides include, but are not limited to, further modified THP compounds having the formula:

[0188] In certain embodiments, modified THP nucleosides are provided wherein q1, q2, q3, q4, q5, q6, and q7 are each H. In certain embodiments, at least one of q1, q2, q3, q4, q5, q6, and q7 is other than H. In certain embodiments, at least one of q1, q2, q3, q4, q5, q6, and q7 is methyl. In certain embodiments, modified THP nucleosides are provided wherein one of R1 and R2 is F. In certain embodiments, R1 is F and R2 is H, in certain embodiments, R1 is methoxy and R2 is H, and in certain embodiments, R1 is methoxyethoxy and R2 is H.

[0189] In certain embodiments, the sugar surrogate comprises a ring having five or more atoms and two or more heteroatoms. For example, their use in nucleosides and oligonucleotides containing morpholino sugar moieties has been reported (see, e.g., Braasch et al., Biochemistry, 2002, 41, 4503-4510, and Summerton et al., US 5,698,685, Summerton et al., US 5,166,315, Summerton et al., US 5,185,444, and Summerton et al., US 5,034,506). As used herein, the term "morpholino" refers to the following structure: [ka] In certain embodiments, morpholinos may be modified, such as by adding or altering various substituents from the morpholino structures described above. Such sugar surrogates are referred to herein as "modified morpholinos."

[0190] In certain embodiments, the sugar surrogate comprises an acyclic moiety. Examples of nucleosides and oligonucleotides containing such acyclic sugar surrogates include peptide nucleic acids ("PNAs"), acyclic butyl nucleic acids (see, e.g., Kumar et al., Org. Biomol. Chem., 2013, 11, 5853-5865), and Manoharan et al. al., WO 2011 / 133876. Many other bicyclic and tricyclic sugar and sugar surrogate ring systems are known in the art and can be used in modified nucleosides.

[0191] 1. Certain modified nucleobases In certain embodiments, the first modified oligonucleotide comprises one or more nucleosides that contain unmodified nucleobases.In certain embodiments, the second modified oligonucleotide comprises one or more nucleosides that contain unmodified nucleobases.In certain embodiments, the modified oligonucleotide, such as the first modified oligonucleotide or the second modified oligonucleotide, comprises one or more nucleosides that contain modified nucleobases.In certain embodiments, the modified oligonucleotide, such as the first modified oligonucleotide or the second modified oligonucleotide, comprises one or more nucleosides that do not contain nucleobases, which are called abasic nucleosides.

[0192] In certain embodiments, the modified nucleobase is a 5-substituted pyrimidine, a 6-azapyrimidine, an azapyrimidine, In certain embodiments, the modified nucleobase is selected from alkyl- or alkynyl-substituted pyrimidines, alkyl-substituted purines, and N-, N-, and O-substituted purines. In certain embodiments, the modified nucleobase is selected from 2-aminopropyladenine, 5-hydroxymethylcytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-N-methylguanine, 6-N-methyladenine, 2-propyladenine, 2-thiouracil, 2-thiothymine, and 2-thiocytosine, 5-propynyl (—C≡C—CH3) uracil, 5-propynylcytosine, 6-azouracil, 6-azocytosine, 6-azothymine, 5-ribosyluracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl, 8-aza, and other 8-substituted purines, 5-halo, particularly 5-bro The bases are selected from N-, 5-trifluoromethyl, 5-halouracil, and 5-halocytosine, 7-methylguanine, 7-methyladenine, 2-N-adenine, 2-aminoadenine, 7-deazaguanine, 7-deazaadenine, 3-deazaguanine, 3-deazaadenine, 6-N-benzoyladenine, 2-N-isobutyrylguanine, 4-N-benzoylcytosine, 4-N-benzoyluracil, 5-methyl 4-N-benzoylcytosine, 5-methyl 4-N-benzoyluracil, universal bases, hydrophobic bases, promiscuous bases, size-expanded bases, and fluorinated bases. Further modified nucleobases include tricyclic pyrimidines, such as 1,3-diazaphenoxazin-2-one, 1,3-diazaphenothiazin-2-one, and 9-(2-aminoethoxy)-1,3-diazaphenoxazin-2-one (G-clamp). Modified nucleobases can also include those in which the purine or pyrimidine base is replaced with other heterocycles, such as 7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine, and 2-pyridone. Additional nucleobases include those described by Merigan et al. al., US 3,687,808, The Concise Encyclopedia Of Polymer Science And Engineering, Kroschwitz, JI, Ed., John Wiley & Sons, 1990, 858-859, Englisch et al., Angewandte Chemie, International Edition, 1991, 30,613, Sanghvi, YS, Chapter 15, Antisense Research and Applications, Crooke, ST and Lebleu, B., Eds., CRC Press, 1993, 273-288, and Antisense Drug Technology, Chapters 6 and 15, Crooke ST, Ed., CRC Press, 2008, 163-166 and 442-443.

[0193] Publications that teach the preparation of some of the above and other modified nucleobases include Manohara et al., US2003 / 0158403, Manoharan et al., US2003 / 0175906, Dinh et al., US4,845,205, Spielvogel et al., US5,130,302, Rogers et al., US5,134,066, Bischofberger et al., US5,175,273, Urdea et al., US5,367,066, Benner et al., US5,432,272, Matteucci et al., US5,434,257, Gmeiner et al., US5,457,187, Cook et al., US5,459,255, Froehler et al. al., US5,484,908, Matteucci et al., US5,502,177, Hawkins et al. al.,US5,525,711, Haralambidis et al.,US5,552,540, Cook et al.,US5,587,469, Froehler et al.,US5,594,121, Switzer et al.,US5,596,091, Cook et al.,US5,614,617, Froehler et al. al., US5,645,985, Cooke et al., US5,681,941, Cook et al., US5,811,534, Cook et al., US5,750,692, Cook et al., US5,948,903, Cook et al., US5,587,470, Cook et al., US5,457,191, Matteucci et al., US5,763,588, Froehler et al., US5,830,653, Cook et al., US5,808,027, Cook et al., US6,166,199, and Matteucci et al., US6,005,096.

[0194] B. Certain modified internucleoside linkages In certain embodiments, any internucleoside linkage may be used to link together the nucleosides of a modified oligonucleotide. In certain embodiments, any internucleoside linkage may be used to link together the nucleosides of a first modified oligonucleotide. In certain embodiments, any internucleoside linkage may be used to link together the nucleosides of a second modified oligonucleotide. Two main types of internucleoside linkage groups are defined by the presence or absence of a phosphorus atom. Representative phosphorus-containing internucleoside linkages include, but are not limited to, phosphodiester linkages ("P=O") (also referred to as unmodified or naturally occurring linkages), phosphotriesters, methylphosphonates, phosphoramidates, and phosphorothioates ("P=S"), and phosphate-containing phosphorodithioates ("HS-P=S"). Representative non-phosphorus-containing internucleoside linkages include, but are not limited to, methylenemethylimino (-CH-N(CH)-O-CH-), thiodiester, thionocarbamate (-OC(=O)(NH)-S-), siloxane (-O-SiH-O-), and N,N'-dimethylhydrazine (-CH-N(CH)-N(CH)-). Modified internucleoside linkages can be used to alter, and typically enhance, the nuclease resistance of oligonucleotides compared to naturally occurring phosphate linkages. In certain embodiments, internucleoside linkages containing chiral atoms can be prepared as racemic mixtures or as separate enantiomers. Representative chiral internucleoside linkages include, but are not limited to, alkylphosphonates and phosphorothioates. Methods for preparing phosphorus-containing and non-phosphorus-containing internucleoside linkages are well known to those skilled in the art.

[0195] Neutral internucleoside linkages include, but are not limited to, phosphotriester, methylphosphonate, MMI (3'-CH2-N(CH3)-O-5'), amide-3 (3'-CH2-C(=O)-N(H)-5'), amide-4 (3'-CH2-N(H)-C(=O)-5'), formacetal (3'-O-CH2-O-5'), methoxypropyl, and thioformacetal (3'-S-CH2-O-5'). Additional neutral internucleoside linkages include nonionic linkages, including siloxane (dialkylsiloxane), carboxylate ester, carboxamide, sulfide, sulfonate ester, and amide (e.g., Carbohydrate Modifications in Antisense Oligonucleotides). Research; YS Sanghvi and PDCook, Eds., ACS Symposium Series 580; Chapters 3 and 4, 40-65. Additional neutral internucleoside linkages include non-ionic linkages containing a mixture of N, O, S, and CH2 moieties.

[0196] C. Specific motifs In certain embodiments, the first modified oligonucleotide comprises one or more modified nucleosides comprising a modified sugar. In certain embodiments, the first modified oligonucleotide comprises one or more modified nucleosides comprising a modified nucleobase. In certain embodiments, the first modified oligonucleotide comprises one or more modified internucleoside linkages. In such embodiments, the first modified oligonucleotide comprises modified, unmodified, and differently modified sugar moieties, nucleobases, and and / or internucleoside linkages define a pattern or motif. In certain embodiments, the sugar moieties, nucleobases, and internucleoside linkage patterns are each independent of one another. Thus, a first modified oligonucleotide can be represented by its sugar motif, nucleobase motif, and / or internucleoside linkage motif (as used herein, nucleobase motif refers to modifications to nucleobases independent of the sequence of the nucleobases).

[0197] In certain embodiments, the second modified oligonucleotide comprises one or more modified nucleosides comprising a modified sugar. In certain embodiments, the second modified oligonucleotide comprises one or more modified nucleosides comprising a modified nucleobase. In certain embodiments, the second modified oligonucleotide comprises one or more modified internucleoside linkages. In such embodiments, the modified, unmodified, and differently modified sugar moieties, nucleobases, and / or internucleoside linkages of the second modified oligonucleotide define a pattern or motif. In certain embodiments, the sugar moieties, nucleobases, and internucleoside linkage patterns are each independent of one another. Thus, the second modified oligonucleotide can be represented by its sugar motif, nucleobase motif, and / or internucleoside linkage motif (as used herein, nucleobase motif refers to modifications to the nucleobases independently of the sequence of the nucleobases).

[0198] In certain embodiments, modified oligonucleotides comprise one or more modified nucleosides comprising a modified sugar. In certain embodiments, modified oligonucleotides comprise one or more modified nucleosides comprising a modified nucleobase. In certain embodiments, modified oligonucleotides comprise one or more modified internucleoside linkages. In such embodiments, the modified, unmodified, and differently modified sugar moieties, nucleobases, and / or internucleoside linkages of the modified oligonucleotides define a pattern or motif. In certain embodiments, the sugar moieties, nucleobases, and internucleoside linkage patterns are each independent of one another. Thus, a modified oligonucleotide can be described by its sugar motif, nucleobase motif, and / or internucleoside linkage motif (as used herein, nucleobase motif refers to modifications to the nucleobases independently of the sequence of the nucleobases).

[0199] 1. Specific glycomotifs In certain embodiments, an oligonucleotide comprises one or more modified and / or unmodified sugar moieties arranged along the oligonucleotide or region thereof in a defined pattern or sugar motif, which in certain instances includes, but is not limited to, any of the sugar modifications discussed herein.

[0200] In certain embodiments, a modified oligonucleotide, such as a first modified oligonucleotide or a second modified oligonucleotide, comprises or consists of a region having a gapmer motif, which comprises two outer regions or "wings" and a central or internal region or "gap." These three regions of a gapmer motif (the 5'-wing, the gap, and the 3'-wing) form a contiguous sequence of nucleosides, in which at least some of the sugar moieties of the nucleosides in each wing are different from at least some of the sugar moieties of the nucleosides in the gap. Specifically, at least the sugar moieties of the nucleosides closest to the gap in each wing (the 3'-most nucleoside of the 5'-wing and the 5'-most nucleoside of the 3'-wing) are different from the sugar moieties of the adjacent gap nucleosides, thereby defining the boundary between the wing and the gap (i.e., the wing / gap junction). In certain embodiments, the sugar moieties within the gap are the same as each other. In certain embodiments, the gap includes one or more nucleosides in which a sugar moiety differs from the sugar moieties of one or more other nucleosides in the gap. In certain embodiments, the sugar motifs of the two wings are identical to each other (symmetric gapmers). In certain embodiments, the sugar motif of the 5'-wing is different from the sugar motif of the 3'-wing (asymmetric gapmers).

[0201] In certain embodiments, both wings of the gapmer comprise 1 to 5 nucleosides. In certain embodiments, both wings of the gapmer comprise 2 to 5 nucleosides. In certain embodiments, both wings of the gapmer comprise 3 to 5 nucleosides. In certain embodiments, all of the nucleosides of the gapmer are modified nucleosides.

[0202] In certain embodiments, the gapmer gap contains 7 to 12 nucleosides. In certain embodiments, the gapmer gap contains 7 to 10 nucleosides. In certain embodiments, the gapmer gap contains 8 to 10 nucleosides. In certain embodiments, the gapmer gap contains 10 nucleosides. In certain embodiments, each nucleoside in the gapmer gap is an unmodified 2'-deoxynucleoside.

[0203] In certain embodiments, the gapmer is a deoxygapmer. In such embodiments, the nucleosides on the gap side of each wing / gap junction are unmodified 2'-deoxynucleosides and the nucleosides on the wing side of each wing / gap junction are modified nucleosides. In certain such embodiments, each nucleoside of the gap is an unmodified 2'-deoxynucleoside. In certain such embodiments, each nucleoside of each wing is a modified nucleoside.

[0204] In certain embodiments, the second modified oligonucleotide comprises a gapmer-like motif, wherein the gapmer wings comprise 1-5 nucleosides and the gapmer gap comprises 2-6 nucleosides. In certain embodiments, each nucleoside of the gapmer gap is an unmodified 2'-deoxynucleoside. In certain embodiments, the second modified oligonucleotide has a gapmer-like motif that does not support RNase H activity, e.g., the second modified oligo has RNA-like wings and a DNA-like gap, but the wings, gap, or overall length of such second modified oligonucleotide are insufficient to support RNase H activity.

[0205] In certain embodiments, the first modified oligonucleotide comprises or consists of a region having a fully modified sugar motif. In such embodiments, each nucleoside of the fully modified region of the modified oligonucleotide comprises a modified sugar moiety. In certain such embodiments, each nucleoside throughout the first modified oligonucleotide comprises a modified sugar moiety. In certain embodiments, the first modified oligonucleotide comprises or consists of a region having a fully modified sugar motif, wherein each nucleoside within the fully modified region comprises the same modified sugar moiety, referred to herein as a uniformly modified sugar motif. In certain embodiments, the fully modified oligonucleotide is a uniformly modified oligonucleotide. In certain embodiments, each nucleoside of the uniform modification comprises the same 2'-modification.

[0206] 2. Specific nucleobase motifs In certain embodiments, an oligonucleotide (including a first modified oligonucleotide and / or a second modified oligonucleotide) comprises modified and / or unmodified nucleobases arranged along the oligonucleotide or region thereof in a defined pattern or motif. In certain embodiments, each nucleobase is modified. In certain embodiments, none of the nucleobases are modified. In certain embodiments, each purine or each pyrimidine is modified. In certain embodiments, each adenine is modified. In certain embodiments, each guanine is modified. In certain embodiments, each thymine is modified. In certain embodiments, each uracil is modified. In certain embodiments, each cytosine is modified. In certain embodiments, some or all of the cytosine nucleobases of a modified oligonucleotide are 5-methylcytosine.

[0207] In certain embodiments, a modified oligonucleotide (e.g., a first modified oligonucleotide or a second modified oligonucleotide) comprises a block of modified nucleobases. In certain such embodiments, the block is at the 3' end of the oligonucleotide. In certain embodiments, the block is within 3 nucleosides of the 3' end of the oligonucleotide. In certain embodiments, the block is at the 5' end of the oligonucleotide. In certain embodiments, the block is within 3 nucleosides of the 5' end of the oligonucleotide.

[0208] In certain embodiments, an oligonucleotide having a gapmer motif comprises nucleosides comprising modified nucleobases. In certain such embodiments, one nucleoside comprising a modified nucleobase is located in the central gap of the oligonucleotide having a gapmer motif. In certain such embodiments, the sugar moiety of the nucleoside is a 2'-deoxyribosyl moiety. In certain embodiments, the modified nucleobase is selected from 2-thiopyrimidine and 5-propynepyrimidine. In certain embodiments, a first modified oligonucleotide has a gapmer motif. In certain embodiments, a first modified oligonucleotide has a gapmer motif and a second modified oligonucleotide does not have a gapmer motif. In certain embodiments, a first modified oligonucleotide has a gapmer motif and a second modified oligonucleotide has a fully modified motif.

[0209] 3. Specific internucleoside linkage motifs In certain embodiments, an oligonucleotide, e.g., a first modified oligonucleotide and / or a second modified oligonucleotide, comprises modified and / or unmodified internucleoside linkages arranged in a defined pattern or motif along the oligonucleotide or a region thereof. In certain embodiments, essentially each internucleoside linkage group is a phosphate internucleoside linkage (P=O). In certain embodiments, each internucleoside linkage group of a modified oligonucleotide is a phosphorothioate (P=S). In certain embodiments, essentially each internucleoside linkage group of a first modified oligonucleotide is a phosphate internucleoside linkage (P=O). In certain embodiments, each internucleoside linkage group of a first modified oligonucleotide is a phosphorothioate (P=S). In certain embodiments, essentially each internucleoside linkage group of a second modified oligonucleotide is a phosphate internucleoside linkage (P=O). In certain embodiments, each internucleoside linkage group of a second modified oligonucleotide is a phosphorothioate (P=S). In certain embodiments, the internucleoside linkage group of each first modified oligonucleotide is independently selected from a phosphorothioate internucleoside linkage and a phosphate internucleoside linkage. In certain embodiments, the internucleoside linkage group of each second modified oligonucleotide is independently selected from a phosphorothioate internucleoside linkage and a phosphate internucleoside linkage. In certain embodiments, the sugar motif of the first modified oligonucleotide is a gapmer, and all internucleoside linkages within the gap are modified. In certain such embodiments, some or all of the wing internucleoside linkages are unmodified phosphate linkages. In certain embodiments, the terminal internucleoside linkages are modified. In certain embodiments, the sugar motif of the second modified oligonucleotide is gapmer-like, and all of the wing internucleoside linkages are unmodified phosphate linkages. In certain such embodiments, the terminal internucleoside linkages are modified.

[0210] D. A specific length In certain embodiments, oligonucleotides (including modified oligonucleotides) can have any length within a range of variations. In certain embodiments, a first modified oligonucleotide can have any length within a range of variations. In certain embodiments, a second modified oligonucleotide can have any length within a range of variations. In certain embodiments, an oligonucleotide consists of X to Y linked nucleosides, where X is the minimum number of nucleosides in that range. and Y represents the maximum number of nucleosides in the range. In certain such embodiments, X and Y are each independently selected from 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, and 50, provided that X≦Y. For example, in certain embodiments, the oligonucleotides may be 6-7, 6-8, 6-9, 6-10, 6-11, 6-12, 7-8, 7-9, 7-10, 7-11, 7-12, 8-9, 8-10, 8-11, 8-12, 9-10, 9-11, 9-12, 10-11, 10-12, 11-12, 12-13, 12-14, 12-15, 12-16, 12-17, 12-18, 12-19, 12-20, 12-21, 12-22, 12-23, 12-24, 12-25, 12-26, 12-27, 12-28, 12-29, 12-30, 12-31, 12-32, 12-33, 12-34, 12-35, 12-36, 12-37, 12-38, 12-39, 12-40, 12-41, 12-42, 12-43, 12-44, 12-45, 12-46, 12-47, 12-48, 12-49, 12-50, 12-51, 12-52, 12-53, 12-54, 12-55, 12-56, 12-57, 12-58, 12-59, 12-60, 12-61, 12-62, 12-63, 12-64, 12-65, 12- 4, 12-25, 12-26, 12-27, 12-28, 12-29, 12-30, 13-14, 13-15, 13-16, 13-17, 13-18, 13-19, 13-20, 13-21, 13-22, 13-23, 13-24, 13-25, 13-26, 13-27, 13-28, 13-29, 13-30, 14-15, 14-16, 14-17, 14-18, 14-19, 14-20, 14-21, 14-22, 14-23, 14- 24, 14-25, 14-26, 14-27, 14-28, 14-29, 14-30, 15-16, 15-17, 15-18, 15-19, 15-20, 15-21, 15-22, 15-23, 15-24, 15-25, 15-26, 15-27, 15-28, 15-29, 15-30, 16-17, 16-18, 16-19, 16-20, 16-21, 16-22, 16-23, 16-24, 16-25, 16-26, 16-27, 1 6-28, 16-29, 16-30, 17-18, 17-19, 17-20, 17-21, 17-22, 17-23, 17-24, 17-25, 17-26, 17-27, 17-28, 17-29, 17-30, 18-19, 18-20, 18-21, 18-22, 18-23, 18-24, 18-25, 18-26, 18-27, 18-28, 18-29, 18-30, 19-20, 19-21, 19-22, 19-23, 19-24,19-25, 19-26, 19-29, 19-28, 19-29, 19-30, 20-21, 20-22, 20-23, 20-24, 20-25, 20-26, 20-27, 20-28, 20-29, 20-30, 21-22, 21-23, 21-24, 21-25, 21-26, 21-27, 21-28, 21-29, 21-30, 22-23, 22-24, 22-25, 22-26, 22-27, 22-28, 22-29 , 22-30, 23-24, 23-25, 23-26, 23-27, 23-28, 23-29, 23-30, 24-25, 24-26, 24-27, 24-28, 24-29, 24-30, 25-26, 25-27, 25-28, 25-29, 25-30, 26-27, 26-28, 26-29, 26-30, 27-28, 27-29, 27-30, 28-29, 28-30, or 29-30 linked nucleosides.

[0211] E. Certain Modified Oligonucleotides In certain embodiments, the above-described modifications (sugar, nucleobase, internucleoside linkage) are incorporated into a first modified oligonucleotide, a second modified oligonucleotide, or both a first and a second modified oligonucleotide. In certain embodiments, a modified oligonucleotide is characterized by its modification motif and overall length. In certain embodiments, each such parameter is independent of the other. Thus, unless otherwise specified, each internucleoside linkage of an oligonucleotide having a gapmer sugar motif may be modified or unmodified, and may or may not follow the gapmer modification pattern of sugar modifications. For example, the internucleoside linkages within the wing regions of a sugar gapmer may be identical or different from each other and may be identical or different from the internucleoside linkages in the gap region of the sugar motif. Similarly, such sugar gapmer oligonucleotides may contain one or more modified nucleobases independent of the gapmer pattern of sugar modifications. Furthermore, in certain instances, oligonucleotides may be characterized by their overall length or extent, and by the presence or absence of two or more regions (e.g., For example, the range may be represented by lengths or ranges of lengths spanning a region containing nucleosides with a particular sugar modification, and in such situations, numbers may be selected for each range that result in an oligonucleotide whose total length falls outside the specified region. In such situations, both elements must be met. For example, in certain embodiments, the modified oligonucleotide is comprised of 15-20 linked nucleosides and has a sugar motif comprised of three regions, A, B, and C, where Region A is comprised of 2-6 linked nucleosides with a particular sugar motif, Region B is comprised of 6-10 linked nucleosides with a particular sugar motif, and Region C is comprised of 2-6 linked nucleosides with a particular sugar motif. Such embodiments do not include modified oligonucleotides in which A and C each consist of 6 linked nucleosides and B consists of 10 linked nucleosides (even though those numbers of nucleosides are allowed within the requirements for A, B, and C), because the total length of such an oligonucleotide would be 22, exceeding the upper total length limit (20) for modified oligonucleotides. Unless an oligonucleotide is specifically described herein with respect to one or more parameters, such parameters are not limited. Thus, if a modified oligonucleotide is described only as having a gapmer sugar motif and no further description exists, the modified oligonucleotide may have any length, internucleoside linkage motif, and nucleobase motif. Unless otherwise specified, all modifications are independent of the nucleobase sequence.

[0212] F. Nucleic Acid Sequence In certain embodiments, oligonucleotides (unmodified or modified) are detailed by their nucleobase sequence. In certain embodiments, the oligonucleotide has a nucleobase sequence that is complementary to a second oligonucleotide or an identified reference nucleic acid, such as a target nucleic acid. In certain such embodiments, a region of the oligonucleotide has a nucleobase sequence that is complementary to a second oligonucleotide or an identified reference nucleic acid, such as a target nucleic acid. In certain embodiments, the nucleobase sequence of a region or the entire length of the oligonucleotide is at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or 100% complementary to a second oligonucleotide or nucleic acid, such as a target nucleic acid.

[0213] II. Certain Oligomeric Compounds In certain embodiments, the present invention provides oligomeric compounds comprising an oligonucleotide (modified or unmodified oligonucleotide, or a first modified oligonucleotide, or a second modified oligonucleotide) and, optionally, one or more linking groups and / or terminal groups. The linking group comprises one or more linking moieties and a linking linker connecting the linking moiety to the oligonucleotide. The linking group may be attached to either or both ends of the oligonucleotide and / or any internal position. In certain embodiments, the linking group is attached to the 2' position of a nucleoside of the modified oligonucleotide. In certain embodiments, the linking group attached to either or both ends of the oligonucleotide is a terminal group. In certain such embodiments, the linking group or terminal group is attached to the 3' and / or 5' end of the oligonucleotide. In certain such embodiments, the linking group (or terminal group) is attached to the 3' end of the oligonucleotide. In certain embodiments, the linking group is attached near the 3' end of the oligonucleotide. In certain embodiments, the linking group (or terminal group) is attached to the 5' end of the oligonucleotide. In certain embodiments, the linking group is attached near the 5' end of the oligonucleotide.

[0214] Examples of terminal groups include, but are not limited to, a linking group, a capping group, a phosphate moiety, a protecting group, a modified or unmodified nucleoside, and two or more nucleosides that are independently modified or unmodified.

[0215] A. Specific Bonding Groups In certain embodiments, an oligonucleotide, such as a first modified oligonucleotide or a second modified oligonucleotide, is covalently linked to one or more linking groups. In certain embodiments, a second modified oligonucleotide is covalently linked to one or more linking groups. In certain embodiments, a second modified oligonucleotide is covalently linked to one or more linking groups, and a first modified oligonucleotide is not linked to a linking group. In certain embodiments, a linking group modifies one or more properties of the oligonucleotide to which it is attached, including, but not limited to, pharmacodynamics, pharmacokinetics, stability, binding, absorption, tissue distribution, intracellular distribution, cellular uptake, charge, and clearance. In certain embodiments, a linking group imparts a new property to the attached oligonucleotide, such as a fluorophore or reporter group that enables detection of the oligonucleotide. Specific linking groups and moieties have been previously described, such as cholesterol moieties (Letsinger et al., Proc. Natl. Acad. Sci. USA, 1989, 86, 6553-6556), cholic acid (Manoharan et al., Bioorg. Med. Chem. Lett., 1994, 4, 1053-1060), thioethers such as hexyl-S-tritylthiol (Manoharan et al., Ann. NY Acad. Sci., 1992, 660, 306-309; Manoharan et al., Bioorg. Med. Chem. Lett., 1993, 3, 2765-2770), thiocholesterol (Oberhauser et al., Nucl. Acids Res., 1992, 20, 533-538), aliphatic chains, for example, dodecane-diol or undecyl residues (Saison-Behmoaras et al., EMBO J., 1991, 10, 1111-1118; Kabanov et al., FEBS Lett., 1990, 259, 327-330; Svinarchuk et al., Biochimie, 1993, 75, 49-54), phospholipids such as di-hexadecyl-rac-glycerol or triethyl-ammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651-3654; Shea et al., Nucl. Acids Res., 1990, 18, 3777-3783), polyamine or polyethylene glycol chains (Manoharan et al., Nucleosides & Nucleotides, 1995, 14, 969-973), or adamantane palmityl acetate moieties (Mishra et al. al., Biochim. Biophys. Acta, 1995, 1264, 229-237), an octadecylamine moiety or a hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., J. Pharmacol. Exp. Ther., 1996, 277, 923-937), a tocopherol group (Nishina et al., Molecular Therapy Nucleic Acids, 2015, 4, e220, and Nishina et al., Molecular Therapy, 2008, 16, 734-740), or a GalNAc cluster (e.g., WO2014 / 179620).

[0216] 1.Joining part Binding moieties include, without limitation, intercalators, reporter molecules, polyamines, polyamides, peptides, carbohydrates, vitamin moieties, polyethylene glycols, thioethers, polyethers, cholesterol, thiocholesterol, cholic acid moieties, folates, lipids, phospholipids, biotin, phenazine, phenanthridine, anthraquinone, adamantane, acridine, fluorescein, rhodamine, coumarin, fluorophores, and dyes.

[0217] In certain embodiments, the binding moiety is an active drug substance, such as aspirin, warfarin, phenylbutazone, ibuprofen, suprofen, fenbufen, ketoprofen, These include (S)-(+)-pranoprofen, carprofen, dansylsarcosine, 2,3,5-triiodobenzoic acid, fingolimod, flufenamic acid, folinic acid, benzothiadiazide, chlorothiazide, diazepines, indomethicine, barbiturates, cephalosporins, sulfa drugs, antidiabetic drugs, antibacterial drugs or antibiotics, and the like.

[0218] 2. Binding Linker The linking moiety is attached to the oligonucleotide via a linking linker. In certain oligomeric compounds, the linking linker is a single chemical bond (i.e., the linking moiety is directly attached to the oligonucleotide via a single bond). In certain embodiments, the linking linker comprises a chain structure such as a hydrocarbyl chain or an oligomer made of repeating units such as ethylene glycol units, nucleoside units, or amino acid units.

[0219] In certain embodiments, the bonded linker comprises one or more groups selected from alkyl, amino, oxo, amide, disulfide, polyethylene glycol, ether, thioether, and hydroxylamino. In certain such embodiments, the bonded linker comprises a group selected from alkyl, amino, oxo, amide, and ether groups. In certain embodiments, the bonded linker comprises a group selected from alkyl and amide groups. In certain embodiments, the bonded linker comprises a group selected from alkyl and ether groups. In certain embodiments, the bonded linker comprises at least one phosphorus moiety. In certain embodiments, the bonded linker comprises at least one phosphate group. In certain embodiments, the bonded linker comprises at least one neutral linking group.

[0220] In certain embodiments, the attachment linker is a bifunctional linking moiety, including those described above, such as those known in the art to be useful for attaching a binding group to a parent compound, such as the oligonucleotides provided herein. Generally, a bifunctional linking moiety contains at least two functional groups. One of the functional groups is selected to form a bond with a specific site on the parent compound, and the other is selected to form a bond with the attachment group. Examples of functional groups used in bifunctional linking moieties include, but are not limited to, electrophiles for reaction with nucleophilic groups and nucleophiles for reaction with electrophilic groups. In certain embodiments, a bifunctional linking moiety contains one or more groups selected from amino, hydroxyl, carboxylic acid, thiol, alkyl, alkenyl, and alkynyl.

[0221] Examples of coupling linkers include, but are not limited to, pyrrolidine, 8-amino-3,6-dioxaoctanoic acid (ADO), succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), and 6-aminohexanoic acid (AHEX or AHA). Other coupling linkers include substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C2-C 10 Alkenyl, or substituted or unsubstituted C2-C 10 This includes, but is not limited to, alkynyl, where a non-limiting list of preferred substituents includes hydroxyl, amino, alkoxy, carboxy, benzyl, phenyl, nitro, thiol, thioalkoxy, halogen, alkyl, aryl, alkenyl, and alkynyl groups.

[0222] In certain embodiments, the linked linker comprises 1 to 10 linker nucleosides. In certain embodiments, the linked linker comprises 2 to 5 linker nucleosides. In certain embodiments, the linked linker comprises exactly 3 linker nucleosides. In certain embodiments, the linked linker comprises a TCA motif. In certain embodiments, such linker nucleosides are modified nucleosides. In certain embodiments, such linker nucleosides comprise modified sugar moieties. In certain embodiments, the linker nucleosides are unmodified. In certain embodiments, the linker nucleosides comprise an optionally protected heterocyclic base selected from a purine, a substituted purine, a pyrimidine, or a substituted pyrimidine. In certain embodiments, In certain embodiments, the cleavable moiety is a nucleoside selected from uracil, thymine, cytosine, 4-N-benzoylcytosine, 5-methylcytosine, 4-N-benzoyl-5-methylcytosine, adenine, 6-N-benzoyladenine, guanine, and 2-N-isobutyrylguanine. Typically, it is desirable for the linker nucleoside to be cleaved from the oligomeric compound after the oligomeric compound reaches the target tissue. Thus, the linker nucleosides are typically linked to each other and to the remainder of the oligomeric compound via a cleavable bond. In certain embodiments, such a cleavable bond is a phosphodiester bond.

[0223] Linker nucleosides are not considered part of the oligonucleotide herein. Thus, in embodiments where an oligomeric compound comprises an oligonucleotide composed of a specific number or range of linked nucleosides and / or a specific percentage of complementarity to a reference nucleic acid, and such oligomeric compound also comprises a linking group comprising a conjugated linker comprising linker nucleosides, those linker nucleosides are not added to the length of the oligonucleotide and are not used in determining the percentage of complementarity of the oligonucleotide to the reference nucleic acid. For example, an oligomeric compound may comprise (1) a modified oligonucleotide consisting of 8 to 30 nucleosides and (2) a linking group comprising 1 to 10 linker nucleosides adjacent to the nucleosides of such modified oligonucleotide. The total number of consecutive linked nucleosides in such an oligomeric compound is greater than 30. Alternatively, an oligomeric compound may comprise a modified oligonucleotide consisting of 8 to 30 nucleosides without a linking group. The total number of consecutive linked nucleosides in such an oligomeric compound is 30 or less. Unless otherwise specified, a coupled linker comprises 10 or fewer linker nucleosides. In certain embodiments, a coupled linker comprises 5 or fewer linker nucleosides. In certain embodiments, a coupled linker comprises 3 or fewer linker nucleosides. In certain embodiments, a coupled linker comprises 2 or fewer linker nucleosides. In certain embodiments, a coupled linker comprises 1 or fewer linker nucleoside.

[0224] In certain embodiments, it is desirable for the linking group to be cleaved from the oligonucleotide. For example, in certain situations, oligomeric compounds containing certain linking moieties are better taken up by certain cell types, and it is desirable for the linking group to be cleaved to release the unlinked oligonucleotide or parent oligonucleotide once the oligomeric compound is taken up. Thus, certain linker moieties may contain one or more cleavable moieties. In certain embodiments, the cleavable moiety is a cleavable bond. In certain embodiments, the cleavable moiety is a group of atoms containing at least one cleavable bond. In certain embodiments, the cleavable moiety comprises a group of atoms having one, two, three, four, or five or more cleavable bonds. In certain embodiments, the cleavable moiety is selectively cleaved inside a cell or an intracellular compartment such as a lysosome. In certain embodiments, the cleavable moiety is selectively cleaved by an endogenous enzyme such as a nuclease.

[0225] In certain embodiments, the cleavable bond is selected from among an amide, an ester, an ether, one or both esters of a phosphodiester, a phosphate ester, a carbamate, or a disulfide. In certain embodiments, the cleavable bond is one or both esters of a phosphodiester. In certain embodiments, the cleavable moiety comprises a phosphate or a phosphodiester. In certain embodiments, the cleavable moiety is a phosphate bond between the oligonucleotide and the linking moiety or linking group.

[0226] In certain embodiments, the cleavable moiety comprises or consists of one or more linker nucleosides. In certain such embodiments, one or more linker nucleosides are linked to each other and / or to the remainder of the oligomeric compound via a cleavable bond. In certain embodiments, such cleavable bond is an unmodified phosphodiester. In certain embodiments, the cleavable moiety is a 2'-deoxynucleoside linked to the 3'- or 5'-terminal nucleoside of the oligonucleotide via a phosphate internucleoside bond and covalently linked to the remainder of the linked linker or moiety via a phosphate or phosphorothioate bond. In certain such embodiments, the cleavable moiety is 2'-deoxyadenosine.

[0227] III. Specific Antisense Compounds In certain embodiments, the present invention provides antisense compounds, which comprise or consist of oligomeric compounds containing antisense oligonucleotides having a nucleobase sequence complementary to that of a target nucleic acid. In certain embodiments, the antisense compounds are single-stranded. Such single-stranded antisense compounds typically comprise or consist of oligomeric compounds comprising or consisting of modified oligonucleotides and optional linking groups. In certain embodiments, the antisense compounds are double-stranded. Such double-stranded antisense compounds comprise a first oligomeric compound having a region complementary to the target nucleic acid and a second oligomeric compound having a region complementary to the first oligomeric compound. The first oligomeric compound of such double-stranded antisense compounds typically comprises or consists of a modified oligonucleotide and optional linking groups. The oligonucleotide of the second oligomeric compound of such double-stranded antisense compounds can be modified or unmodified and optionally contains a linking group. One or both of the oligomeric compounds of the double-stranded antisense compounds can contain a linking group. Oligomeric compounds of double-stranded antisense compounds may include non-complementary overhanging nucleosides.

[0228] In certain embodiments, the oligomeric compound of the antisense compound can hybridize with the target nucleic acid, thereby producing at least one antisense activity. In certain embodiments, the antisense compound selectively affects one or more target nucleic acids. Such selective antisense compounds include a nucleobase sequence that hybridizes with one or more target nucleic acids to produce one or more desired antisense activities, and does not hybridize with one or more non-target nucleic acids, or a nucleobase sequence that does not hybridize with one or more non-target nucleic acids so as not to produce significant undesired antisense activity.

[0229] In certain antisense activities, hybridization of an antisense compound to a target nucleic acid results in the recruitment of a protein that cleaves the target nucleic acid. For example, certain antisense compounds result in RNase H-mediated cleavage of the target nucleic acid. RNase H is an intracellular endonuclease that cleaves the RNA strand of an RNA:DNA duplex. The DNA in such an RNA:DNA duplex need not be unmodified DNA. In certain embodiments, the present invention provides antisense compounds that are sufficiently "DNA-like" to induce RNase H activity. Furthermore, in certain embodiments, the gap of a gapmer is permitted to contain one or more non-DNA-like nucleosides.

[0230] In certain antisense activity, antisense compound or part of antisense compound is loaded into RNA-induced silencing complex (RISC), which ultimately causes target nucleic acid to be cut.For example, certain antisense compound causes target nucleic acid to be cut by Argonaute.The antisense compound loaded into RISC is RNAi compound.RNAi compound can be double-stranded (siRNA) or single-stranded (ssRNA).

[0231] In certain embodiments, hybridization of an antisense compound to a target nucleic acid does not result in the recruitment of a protein that cleaves the target nucleic acid. In certain such embodiments, hybridization of an antisense compound to a target nucleic acid results in altered splicing of the target nucleic acid. In certain embodiments, hybridization of an antisense compound to a target nucleic acid does not result in the recruitment of a protein that cleaves the target nucleic acid. Hybridization with an acid inhibits the binding interaction between the target nucleic acid and a protein or other nucleic acid. In certain such embodiments, hybridization of the antisense compound to the target nucleic acid results in translational modification of the target nucleic acid.

[0232] Antisense activity can be observed directly or indirectly, hi certain embodiments, observing or detecting antisense activity involves observing or detecting a change in the amount of a target nucleic acid or a protein encoded by such a target nucleic acid, a change in the ratio of splice variants of the nucleic acid or protein, and / or a change in phenotype in a cell or animal.

[0233] IV. Specific Hemiduplexes In certain embodiments, the present disclosure provides half-duplex oligomeric compounds and half-duplex antisense compounds. The half-duplex oligomeric compounds comprise a first modified oligonucleotide and a second modified oligonucleotide, wherein the first modified oligonucleotide has 14 to 30 linked nucleosides and a nucleobase sequence complementary to the nucleobase sequence of the second oligomeric compound and a nucleic acid target, and the second modified oligonucleotide has 6 to 12 linked nucleosides. In the half-duplex, the second oligomeric compound is shorter than the first oligomeric compound. For example, in certain embodiments, the second oligomeric compound is 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 nucleobases shorter in length than the first oligomeric compound.

[0234] In certain embodiments, the first modified oligonucleotide is complementary to the target nucleic acid. In certain such embodiments, the first modified oligonucleotide is a gapmer as described above. Therefore, in such embodiments, the first oligomeric compound can hybridize with the target nucleic acid and induce the cleavage of the target nucleic acid by RNase H. In certain such embodiments, the first modified oligonucleotide is fully modified and does not induce the cleavage of the target nucleic acid via RNase H. In certain such embodiments, the first modified oligonucleotide is fully modified and can regulate the splicing of a given target nucleic acid.

[0235] In certain such embodiments, the second oligomeric compound improves the properties of the first oligomeric compound compared to the absence of such shorter second oligomeric compound. In certain such embodiments, the second oligomeric compound improves the properties of the first oligomeric compound compared to when such second oligomeric compound is equal to or longer than the length of the first oligomeric compound. In certain embodiments, the improved property is one or more of distribution to a target tissue, uptake into target cells, potency, and / or efficacy. In certain embodiments, the improved property is crossing the blood-brain barrier. In certain embodiments, the improved property is crossing the blood-brain barrier, allowing systemic administration of the hemiduplex to reduce target nucleic acids in CNS tissue. In certain embodiments, the target tissue is in the CNS. In certain embodiments, the target tissue is muscle tissue. In certain embodiments, the target tissue is other than the liver (extrahepatic). In certain embodiments, it is desirable to reduce targets in more than one tissue. In certain such embodiments, it is desirable to reduce targets in the liver and one or more other tissues. In certain embodiments, it is desirable to deplete targets in two or more extrahepatic tissues.

[0236] In certain embodiments, the first oligonucleotide of the hemiduplex is a gapmer. In certain such embodiments, the wings of the gapmer comprise 2'-MOE modified nucleosides. In certain embodiments, the wings of the gapmer comprise cEt nucleosides. In certain embodiments, the wings of the gapmer comprise LNA nucleosides. In certain embodiments, both wings of the gapmer comprise at least one 2'-MOE modified nucleoside and at least one bicyclic nucleoside. In certain such embodiments, the Each such bicyclic nucleoside is selected from among an LNA nucleoside and a cEt nucleoside. In certain embodiments, the gap is comprised of 7 to 10 2'-deoxynucleosides.

[0237] In certain embodiments, the second oligonucleotide of the half-duplex has a motif consisting of cEt nucleosides and DNA nucleosides. For example, the second oligonucleotide may have an ABC motif, where A and C are RNA-like nucleosides and B is a DNA-like nucleoside. In certain embodiments, A and C are selected from either cEt or LNA, and B is one or more 2'-deoxynucleosides. In certain embodiments, the second oligonucleotide of the half-duplex has an ABC motif selected from 4-2-3, 2-4-2, and 3-2-4. In certain embodiments, the second oligonucleotide comprises at least one bicyclic nucleoside. In certain embodiments, the bicyclic nucleoside is selected from cEt or LNA. In certain embodiments, the second oligonucleotide of the half-duplex has one or more 2'-deoxynucleosides.

[0238] In certain embodiments, the second oligonucleotide comprises at least one 2'-MOE nucleoside. In certain embodiments, the second oligonucleotide comprises 2'-MOE and 2'-deoxynucleosides. In certain embodiments, the second oligonucleotide comprises at least one bicyclic nucleoside. In certain embodiments, the second oligonucleotide comprises at least one cEt nucleoside. In certain embodiments, the second oligonucleotide comprises at least one LNA nucleoside. In certain embodiments, the second oligonucleotide comprises cEt and 2'-deoxynucleosides. In certain embodiments, the second oligonucleotide has sugar motifs that alternate in modified form (including unmodified). In certain such embodiments, the sugar motif of the second oligonucleotide alternates between 2'-MOE nucleosides and 2'-deoxynucleosides. In certain such embodiments, the sugar motif of the second oligonucleotide alternates between cEt nucleosides and 2'-deoxynucleosides. In certain embodiments, the second oligonucleotide has a sugar motif similar to a gapmer (as described above), except that it may not induce cleavage of the target nucleic acid. Such gapmer-like motifs have a central region flanked by wing regions. In certain such embodiments, the central region is composed of 2'-deoxynucleosides, and the wing regions are cEt-modified nucleosides. In certain such embodiments, the central region is composed of 2'-deoxynucleosides, and the wing regions are LNA-modified nucleosides. In certain embodiments, the central region is composed of 2'-deoxynucleosides, and the wing regions are 2'-MOE-modified nucleosides. The internucleoside linkages of the second oligonucleotide can be modified or phosphodiester. In certain embodiments, the internucleoside linkages of the second oligonucleotide follow a gapmer-like motif, with both wings being phosphorothioate and the center being phosphodiester. Such internucleoside linkage motifs may or may not follow the sugar motif.

[0239] In certain embodiments, at least one of the first and second oligomeric compounds comprises a linking group (as described above). Typically, the second oligomeric compound comprises a linking group. The linking group may be attached to either the 3' or 5' end of the oligomeric compound. In certain embodiments, linking groups are attached to both ends.

[0240] V. Specific Target Nucleic Acids In certain embodiments, the antisense compound comprises or consists of an oligonucleotide comprising a region complementary to a target nucleic acid. In certain embodiments, the target nucleic acid is an endogenous RNA molecule. In certain embodiments, the target nucleic acid encodes a protein. In certain such embodiments, the target nucleic acid is selected from mRNA and pre-mRNA, including intronic regions, exon regions, and untranslated regions. In certain embodiments, the target RNA is mRNA. In certain embodiments, the target nucleic acid is a pre-mRNA. In certain such embodiments, the target region is entirely within an intron. In certain embodiments, the target region spans an intron / exon junction. In certain embodiments, the target region is at least 50% within an intron.

[0241] In certain embodiments, the target nucleic acid is a non-coding RNA. In certain such embodiments, the target non-coding RNA is selected from long non-coding RNA, short non-coding RNA, intronic RNA molecules, snoRNA, scaRNA, microRNA (including pre-microRNA and mature microRNA), ribosomal RNA, and promoter-guided RNA. In certain embodiments, the target nucleic acid is a nucleic acid other than a mature mRNA. In certain embodiments, the target nucleic acid is a nucleic acid other than a mature mRNA or a microRNA. In certain embodiments, the target nucleic acid is a non-coding RNA other than a microRNA. In certain embodiments, the target nucleic acid is a non-coding RNA other than the intron region of a microRNA or pre-mRNA. In certain embodiments, the target nucleic acid is a long non-coding RNA. In certain embodiments, the target nucleic acid is a non-coding RNA associated with the splicing of other pre-mRNAs. In certain embodiments, the target nucleic acid is a non-coding RNA accumulated in the nucleus.

[0242] In certain embodiments, the antisense compounds described herein are complementary to target nucleic acids that contain single nucleotide polymorphisms (SNPs).In certain such embodiments, the antisense compounds can regulate the expression of one allele of the target nucleic acid that contains SNPs to a greater or lesser extent than it regulates another allele.In certain embodiments, the antisense compounds hybridize with the target nucleic acid that contains SNPs at the site of the single nucleotide polymorphism.

[0243] In certain embodiments, antisense compounds are at least partially complementary to more than one target nucleic acid. For example, antisense compounds of the invention can mimic microRNAs and typically bind to multiple targets.

[0244] A. Complementarity / Mismatch to Target Nucleic Acid In certain embodiments, antisense compounds comprise antisense oligonucleotides, which are complementary to a target nucleic acid over their entire length. In certain embodiments, such oligonucleotides are 99% complementary to a target nucleic acid. In certain embodiments, such oligonucleotides are 95% complementary to a target nucleic acid. In certain embodiments, such oligonucleotides are 90% complementary to a target nucleic acid. In certain embodiments, such oligonucleotides are 85% complementary to a target nucleic acid. In certain embodiments, such oligonucleotides are 80% complementary to a target nucleic acid. In certain embodiments, an antisense oligonucleotide is at least 80% complementary to a target nucleic acid over the entire length of the oligonucleotide, and includes a region that is 100% or fully complementary to the target nucleic acid. In certain such embodiments, the region of complete complementarity is 6-20 nucleobases in length. In certain such embodiments, the region of complete complementarity is 10-18 nucleobases in length. In certain such embodiments, the region of complete complementarity is 18-20 nucleobases in length.

[0245] In certain embodiments, the oligomeric compound of an antisense compound contains one or more mismatched nucleobases relative to the target nucleic acid. In certain such embodiments, such mismatches reduce antisense activity against the target, while significantly suppressing activity against non-targets. Thus, certain such embodiments improve the selectivity of the antisense compound. In certain such embodiments, mismatches are specifically located within an oligonucleotide having a gapmer motif. In certain such embodiments, the mismatches are located at positions 1, 2, 3, 4, 5, 6, 7, or 8 from the 5' end of the gap region. In certain such embodiments, the mismatches are located at positions 9, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18 from the 3' end of the gap region. In certain such embodiments, the mismatch is at position 7, 6, 5, 4, 3, 2, or 1. In certain such embodiments, the mismatch is at position 1, 2, 3, or 4 from the 5' end of the wing region. In certain such embodiments, the mismatch is at position 4, 3, 2, or 1 from the 3' end of the wing region.

[0246] B. Specific target nucleic acids in specific tissues In certain embodiments, the antisense compound comprises or consists of an oligonucleotide comprising a region complementary to the target nucleic acid, wherein the target nucleic acid is expressed in extrahepatic tissue.Extrahepatic tissues include, but are not limited to, skeletal muscle, cardiac muscle, smooth muscle, adipose tissue, white fat, spleen, bone, intestine, adrenal gland, testis, ovary, pancreas, pituitary gland, prostate, skin, uterus, bladder, brain, glomerulus, distal tubular epithelium, breast, lung, heart, kidney, ganglion, frontal cortex, spinal cord, trigeminal ganglion, sciatic nerve, dorsal root ganglion, epididymal fat, diaphragm, pancreas and colon tissue.Extrahepatic tissues include, but are not limited to, CNS tissue, such as the brain.

[0247] I. Certain Pharmaceutical Compositions In certain embodiments, the present invention provides pharmaceutical compositions comprising one or more antisense compounds or salts thereof. In certain such embodiments, the pharmaceutical composition comprises a suitable pharmacologically acceptable diluent or carrier. In certain embodiments, the pharmaceutical composition comprises sterile saline and one or more antisense compounds. In certain embodiments, such pharmaceutical compositions consist of sterile saline and one or more antisense compounds. In certain embodiments, the sterile saline is pharmaceutical-grade saline. In certain embodiments, the pharmaceutical composition comprises one or more antisense compounds and sterile water. In certain embodiments, the pharmaceutical composition consists of an antisense compound and sterile water. In certain embodiments, the sterile water is pharmaceutical-grade water. In certain embodiments, the pharmaceutical composition comprises one or more antisense compounds and phosphate-buffered saline (PBS). In certain embodiments, the pharmaceutical composition consists of one or more antisense compounds and sterile PBS. In certain embodiments, the sterile PBS is pharmaceutical-grade PBS.

[0248] In certain embodiments, pharmaceutical compositions comprise one or more antisense compounds and one or more additives, hi certain such embodiments, the additive is selected from water, saline, alcohol, polyethylene glycol, gelatin, lactose, amylase, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, and polyvinylpyrrolidone.

[0249] In certain embodiments, antisense compounds may be mixed with pharmacologically acceptable active and / or inactive substances to prepare pharmaceutical compositions or formulations. The compositions and methods for formulating pharmaceutical compositions vary depending on a number of criteria, including, but not limited to, the route of administration, the extent of the disease, or the dosage to be administered.

[0250] In certain embodiments, pharmaceutical compositions containing antisense compounds include any pharmacologically acceptable salt of the antisense compound, an ester of the antisense compound, or a salt of such an ester. In certain embodiments, pharmaceutical compositions containing antisense compounds, including one or more antisense oligonucleotides, can provide (directly or indirectly) biologically active metabolites or residues thereof upon administration to an animal, such as a human. Thus, for example, the present disclosure also relates to pharmacologically acceptable salts of antisense compounds, prodrugs, pharmacologically acceptable salts of such prodrugs, and other bioequivalents. Suitable pharmacologically acceptable salts include, but are not limited to, sodium and potassium salts. In certain embodiments, prodrugs contain one or more linking groups attached to the oligonucleotide, where the linking groups are cleaved by endogenous nucleases in the body.

[0251] Lipid moieties are used in various ways in nucleic acid medicine. In certain such methods, nucleic acids such as antisense compounds are introduced into preformed liposomes or lipoplexes made with a mixture of cationic lipids and neutral lipids. In certain methods, DNA complexes with monocationic or polycationic lipids are formed in the absence of neutral lipids. In certain embodiments, the lipid moiety is selected to increase the distribution of the pharmaceutical agent to specific cells or tissues. In certain embodiments, the lipid moiety is selected to increase the distribution of the pharmaceutical agent to adipose tissue. In certain embodiments, the lipid moiety is selected to increase the distribution of the pharmaceutical agent to muscle tissue.

[0252] In certain embodiments, the pharmaceutical composition comprises a delivery system. Examples of delivery systems include, but are not limited to, liposomes and emulsions. Certain delivery systems are useful for preparing certain pharmaceutical compositions, such as pharmaceutical compositions containing hydrophobic compounds. In certain embodiments, certain organic solvents, such as dimethyl sulfoxide, are used.

[0253] In certain embodiments, a pharmaceutical composition comprises one or more tissue-specific delivery molecules designed to deliver one or more pharmaceutical agents of the invention to a particular tissue or cell type, for example, in certain embodiments, a pharmaceutical composition comprises a liposome coated with a tissue-specific antibody.

[0254] In certain embodiments, the pharmaceutical composition includes a cosolvent system. Some such cosolvent systems include, for example, benzyl alcohol, a nonpolar surfactant, a water-miscible organic polymer, and an aqueous phase. In certain embodiments, such cosolvent systems are used for hydrophobic compounds. A non-limiting example of such a cosolvent system is the VPD cosolvent system, which is an absolute ethanol solution containing 3% w / v benzyl alcohol, 8% w / v of the nonpolar surfactant Polysorbate 80™, and 65% w / v polyethylene glycol 300. The proportions of such cosolvent systems can vary considerably without significantly altering their solubility and toxicity characteristics. Furthermore, the identity of the cosolvent components can vary; for example, other surfactants can be substituted for Polysorbate 80™, the fractional amount of polyethylene glycol can vary, polyethylene glycol can be replaced by other biocompatible polymers, such as polyvinylpyrrolidone, and other sugars or polysaccharides can be used in place of dextrose.

[0255] In certain embodiments, the pharmaceutical composition is prepared for oral administration. In certain embodiments, the pharmaceutical composition is prepared for buccal administration. In certain embodiments, the pharmaceutical composition is prepared for administration by injection (e.g., intravenous, subcutaneous, intramuscular, etc.). In some such embodiments, the pharmaceutical composition includes a carrier and is formulated in an aqueous solution such as water or a physiologically compatible buffer, such as Hank's solution, Ringer's solution, or physiological saline buffer. In certain embodiments, other ingredients are included (e.g., ingredients that aid solubility or act as preservatives). In certain embodiments, injectable suspensions are prepared using appropriate liquid carriers, suspending agents, etc. Certain pharmaceutical compositions for injection are presented in unit dosage form, e.g., in ampoules or multi-dose containers. Certain pharmaceutical compositions for injection are suspensions, solutions, or emulsions in oily or aqueous vehicles and may contain formulatory agents such as suspending, stabilizing, and / or dispersing agents. Particular solvents suitable for use in injectable pharmaceutical compositions include, but are not limited to, lipophilic solvents and fatty oils such as sesame oil, synthetic fatty acid esters, such as ethyl oleate or triglycerides, and liposomes.

[0256] Non-Limiting Disclosure and Incorporation by Reference Each of the references and patent publications mentioned herein is incorporated by reference in its entirety.

[0257] While the particular compounds, compositions, and methods described herein have been specifically described according to particular embodiments, the following examples are used solely to illustrate the compounds described herein and are not intended to limit them. Each of the references, GenBank accession numbers, etc. described in this application is incorporated herein by reference in its entirety.

[0258] Although each sequence in the sequence listing accompanying this application is identified as either "RNA" or "DNA," as appropriate, in practice, these sequences may be modified using any combination of chemical modifications. Those of skill in the art will readily understand that the designation "RNA" or "DNA" to describe a modified oligonucleotide is, in some cases, arbitrary. For example, an oligonucleotide containing a nucleoside containing a 2'-OH sugar moiety and a thymine base could be designated as a DNA with a modified sugar (a 2'-OH in place of a single 2'-H in DNA) or as an RNA with a modified base (thymine (methylated uracil) in place of uracil in RNA). Thus, the nucleic acid sequences provided herein, including but not limited to those set forth in the sequence listing, are intended to encompass nucleic acids containing any combination of natural or modified RNA and / or DNA, including, but not limited to, nucleic acids with modified nucleobases. By way of further example and without limitation, an oligomeric compound having the nucleobase sequence "ATCGATCG" includes any oligomeric compound having such a nucleobase sequence, whether modified or unmodified, including, but not limited to, compounds containing RNA bases and some RNA bases such as "AUCGATCG", such as an RNA base with the sequence "AUCGAUCG" and an RNA base with some DNA bases, and also other modified nucleobases, e.g., "AT m CGAUCG" and the like, where m C denotes a cytosine base containing a methyl group at the 5-position.

[0259] Certain compounds described herein (e.g., modified oligonucleotides) possess one or more asymmetric centers, which give rise to enantiomers, diastereomers, and other stereoisomeric configurations, which may be defined in terms of absolute stereochemistry as (R) or (S), α or β, as in sugar anomers, or (D) or (L), as in amino acids, etc. The compounds provided herein include all possible isomers, including their racemic and optically pure forms, unless otherwise specified. Similarly, all cis and trans isomers and tautomers are included unless otherwise specified. Unless otherwise specified, the compounds described herein are intended to include the corresponding salt forms. Scope of claims at the time of international application [Section 1] A compound comprising a first oligomeric compound and a second oligomeric compound, wherein the first oligomeric compound comprises a first modified oligonucleotide consisting of 14 to 30 linked nucleosides and has a nucleic acid base sequence complementary to the nucleic acid base sequence of the second oligomeric compound and a nucleic acid target, and the second oligomeric compound comprises a second modified oligonucleotide consisting of 6 to 12 linked nucleosides. [Section 2] 2. The compound of claim 1, wherein the first modified oligonucleotide has a nucleobase sequence that is at least 80% complementary to the nucleobase sequence of the target nucleic acid when measured across the entire nucleobase sequence of the first modified oligonucleotide. [Section 3] 2. The compound of claim 1, wherein the first modified oligonucleotide has a nucleobase sequence that is at least 90% complementary to the nucleobase sequence of the target nucleic acid when measured across the entire nucleobase sequence of the first modified oligonucleotide. [Section 4] 2. The compound of claim 1, wherein the first modified oligonucleotide has a nucleobase sequence that is 100% complementary to the nucleobase sequence of the target nucleic acid when measured across the entire nucleobase sequence of the first modified oligonucleotide. [Section 5] 5. The compound according to claim 1, wherein the first modified oligonucleotide comprises at least five consecutive linked 2'-deoxynucleosides. [Section 6] 5. The compound according to claim 1, wherein the first modified oligonucleotide comprises at least 6 consecutive linked 2'-deoxynucleosides. [Section 7] 5. The compound according to claim 1, wherein the first modified oligonucleotide comprises at least 7 consecutive linked 2'-deoxynucleosides. [Section 8] 5. The compound according to claim 1, wherein the first modified oligonucleotide comprises at least 8 consecutive linked 2'-deoxynucleosides. [Section 9] The compound according to any one of claims 1 to 8, wherein the compound is not an RNAi compound. [Section 10] 9. The compound according to claim 1, wherein the first modified oligonucleotide is a gapmer. [Section 11] 11. The compound according to claim 1, wherein the first modified oligonucleotide has at least 8 consecutive nucleobases of SEQ ID NO:2. [Section 12] 11. The compound according to claim 1, wherein the first modified oligonucleotide has at least 9 consecutive nucleobases of SEQ ID NO:2. [Section 13] 11. The compound according to claim 1, wherein the first modified oligonucleotide has at least 10 consecutive nucleobases of SEQ ID NO:2. [Section 14] 11. The compound according to claim 1, wherein the first modified oligonucleotide has at least 11 consecutive nucleobases of SEQ ID NO:2. [Section 15] 11. The compound according to claim 1, wherein the first modified oligonucleotide has at least 12 consecutive nucleobases of SEQ ID NO:2. [Section 16] 6. The compound according to claim 1, wherein the first modified oligonucleotide comprises at least one modified nucleoside. [Section 17] 17. The compound of claim 16, wherein the first modified oligonucleotide comprises at least one modified nucleoside comprising a modified sugar moiety. [Section 18] 18. The compound of claim 17, wherein the first modified oligonucleotide comprises at least one modified nucleoside comprising a bicyclic sugar moiety. [Section 19] 19. The compound of claim 18, wherein the first modified oligonucleotide comprises at least one modified nucleoside comprising a bicyclic sugar moiety having a 2'-4' bridge, wherein the 2'-4' bridge is selected from -O-CH2- and -O-CH(CH3)-. [Section 20] 20. The compound of claim 1, wherein the first modified oligonucleotide comprises at least one modified nucleoside comprising a bicyclic sugar moiety selected from cEt or LNA. [Section 21] 20. The compound of claim 1, wherein the first modified oligonucleotide comprises at least one modified nucleoside comprising a cEt bicyclic sugar moiety. [Section 22] 22. The compound of claim 1, wherein the first modified oligonucleotide comprises at least one modified nucleoside comprising a modified non-bicyclic sugar moiety. [Section 23] 23. The compound of claim 22, wherein the first modified oligonucleotide comprises at least one modified nucleoside comprising a non-bicyclic sugar moiety comprising 2'-MOE or 2'-OMe. [Section 24] 24. The compound of claim 23, wherein the first modified oligonucleotide comprises at least one modified nucleoside comprising a 2'-MOE modified nucleoside. [Section 25] 25. The compound of claim 1, wherein the first modified oligonucleotide comprises at least one modified nucleoside that comprises a sugar surrogate. [Section 26] 26. The compound of claim 25, wherein the first modified oligonucleotide comprises at least one modified nucleoside comprising a sugar surrogate selected from morpholino, PNA, F-HNA, THP, or modified THP. [Section 27] the first modified oligonucleotide comprising: a 5'-region consisting of 1 to 5 linked 5'-nucleosides; a central region consisting of 6 to 10 linked central region nucleosides, and A 3'-region consisting of 1 to 5 linked 3'-nucleosides wherein each of the 5'-region nucleosides and each of the 3'-region comprises a modified sugar moiety, and each of the central region nucleosides comprises an unmodified DNA sugar moiety. [Section 28] the first modified oligonucleotide comprising: a 5'-region consisting of 5 linked 5'-nucleosides; a central region consisting of 10 linked central region nucleosides, and A 3'-region consisting of five linked 3'-nucleosides wherein each of the 5'-region nucleosides and each of the 3'-region comprises a modified sugar moiety, and each of the central region nucleosides comprises an unmodified DNA sugar moiety. [Section 29] the first modified oligonucleotide comprising: a 5'-region consisting of three linked 5'-nucleosides, a central region consisting of 10 linked central region nucleosides, and A 3'-region consisting of three linked 3'-nucleosides wherein each of the 5'-region nucleosides and each of the 3'-region comprises a modified sugar moiety, and each of the central region nucleosides comprises an unmodified DNA sugar moiety. [Section 30] 25. The compound of any one of claims 1 to 17 or 23 to 24, wherein each nucleoside of the first modified oligonucleotide comprises a non-bicyclic sugar moiety that includes a 2'-MOE. [Section 31] 24. The compound of any one of claims 1-17 or 23, wherein each nucleoside of the first modified oligonucleotide comprises a non-bicyclic sugar moiety that includes 2'-OMe. [Section 32] 27. The compound of any one of claims 1-17 or 25-26, wherein each nucleoside of the first modified oligonucleotide comprises a sugar surrogate selected from morpholino, PNA, F-HNA, THP, or modified THP. [Section 33] 33. The compound of any one of claims 1 to 26 or 30 to 32, wherein the first modified oligonucleotide consists of 14 to 22 linked nucleosides. [Section 34] 33. The compound of any one of claims 1 to 26 or 30 to 32, wherein the first modified oligonucleotide consists of 14 to 20 linked nucleosides. [Section 35] 33. The compound of any one of claims 1 to 26 or 30 to 32, wherein the first modified oligonucleotide consists of 16 to 20 linked nucleosides. [Section 36] 33. The compound of any one of claims 1 to 26 or 30 to 32, wherein the first modified oligonucleotide consists of 16 to 18 linked nucleosides. [Section 37] 33. The compound of any one of claims 1 to 26 or 30 to 32, wherein the first modified oligonucleotide consists of 16 linked nucleosides. [Section 38] 33. The compound of any one of claims 1 to 26 or 30 to 32, wherein the first modified oligonucleotide consists of 20 linked nucleosides. [Section 39] 39. The compound of any one of claims 1 to 38, wherein the first modified oligonucleotide comprises at least one modified internucleoside linkage. [Section 40] 40. The compound of claim 39, wherein each internucleoside linkage of the first modified oligonucleotide is a modified internucleoside linkage. [Section 41] 41. The compound of claim 39 or 40, wherein at least one internucleoside linkage of said first oligonucleotide is a phosphorothioate internucleoside linkage. [Section 42] 40. The compound of any one of claims 1 to 39, wherein the first modified oligonucleotide comprises at least one unmodified phosphodiester internucleoside linkage. [Section 43] 43. The compound according to any one of claims 1 to 42, wherein each internucleoside linkage of the first oligonucleotide is either an unmodified phosphodiester internucleoside linkage or a phosphorothioate internucleoside linkage. [Section 44] 41. The compound of claim 40, wherein each internucleoside linkage of said first oligonucleotide is a phosphorothioate internucleoside linkage. [Section 45] 45. The compound of claim 1, wherein the second modified oligonucleotide is at least 75% complementary to the first modified oligonucleotide over the length of the second modified nucleotide. [Section 46] 45. The compound of claim 1, wherein the second modified oligonucleotide is at least 80% complementary to the first modified oligonucleotide over the length of the second modified nucleotide. [Section 47] 45. The compound of claim 1, wherein the second modified oligonucleotide is at least 90% complementary to the first modified oligonucleotide over the length of the second modified nucleotide. [Section 48] 45. The compound of claim 1, wherein the second modified oligonucleotide is at least 100% complementary to the first modified oligonucleotide over the length of the second modified nucleotide. [Section 49] 49. The compound of any one of claims 1 to 48, wherein the second modified oligonucleotide has at least 6 consecutive nucleobases of SEQ ID NO:4. [Section 50] 49. The compound of any one of claims 1 to 48, wherein the second modified oligonucleotide has at least 6 consecutive nucleobases of SEQ ID NO:5. [Section 51] 51. The compound of any one of claims 1 to 50, wherein the second modified oligonucleotide comprises at least one modified nucleoside. [Section 52] 52. The compound of claim 51, wherein the second modified oligonucleotide comprises at least one modified nucleoside comprising a modified sugar moiety. [Section 53] 53. The compound of claim 52, wherein the second modified oligonucleotide comprises at least one modified nucleoside comprising a bicyclic sugar moiety. [Section 54] 54. The compound of claim 53, wherein the second modified oligonucleotide comprises at least one modified nucleoside comprising a bicyclic sugar moiety having a 2'-4' bridge, wherein the 2'-4' bridge is selected from -O-CH2- and -O-CH(CH3)-. [Section 55] 55. The compound of claim 54, wherein the second modified oligonucleotide comprises at least one modified nucleoside comprising a bicyclic sugar moiety selected from among cEt or LNA. [Section 56] 55. The compound of claim 54, wherein the second modified oligonucleotide comprises at least one modified nucleoside comprising a cEt bicyclic sugar moiety. [Section 57] 57. The compound of any of claims 41-56, wherein the second modified oligonucleotide comprises at least one modified nucleoside comprising a modified non-bicyclic sugar moiety. [Section 58] 58. The compound of claim 57, wherein the second modified oligonucleotide comprises at least one modified nucleoside comprising a non-bicyclic sugar moiety comprising 2'-MOE or 2'-OMe. [Section 59] 59. The compound of any one of claims 1 to 58, wherein the second modified oligonucleotide comprises at least one modified nucleoside that comprises a sugar surrogate. [Section 60] 60. The compound of claim 59, wherein the second modified oligonucleotide comprises at least one modified nucleoside comprising a sugar surrogate selected from morpholino, PNA, F-HNA, THP, or modified THP. [Section 61] the second modified oligonucleotide comprising: a 5'-region consisting of 2 to 4 linked 5'-nucleosides; a central region consisting of 2 to 4 linked central region nucleosides, and A 3'-region consisting of 2 to 4 linked 3'-nucleosides wherein each of the 5'-region nucleosides and each of the 3'-region comprises a modified sugar moiety, and each of the central region nucleosides comprises an unmodified DNA sugar moiety. [Section 62] the second modified oligonucleotide comprising: a 5'-region consisting of two linked 5'-nucleosides, a central region consisting of four linked central region nucleosides, and A 3'-region consisting of two linked 3'-nucleosides wherein each of the 5'-region nucleosides and each of the 3'-region comprises a modified sugar moiety, and each of the central region nucleosides comprises an unmodified DNA sugar moiety. [Section 63] the second modified oligonucleotide comprising: a 5'-region consisting of four linked 5'-nucleosides; a central region consisting of two linked central region nucleosides, and A 3'-region consisting of three linked 3'-nucleosides wherein each of the 5'-region nucleosides and each of the 3'-region comprises a modified sugar moiety, and each of the central region nucleosides comprises an unmodified DNA sugar moiety. [Section 64] the second modified oligonucleotide comprising: a 5'-region consisting of three linked 5'-nucleosides, a central region consisting of 5 linked central region nucleosides, and A 3'-region consisting of three linked 3'-nucleosides wherein each of the 5'-region nucleosides and each of the 3'-region comprises a modified sugar moiety, and each of the central region nucleosides comprises an unmodified RNA sugar moiety. [Section 65] 59. The compound of claim 1, wherein each nucleoside of the second modified oligonucleotide comprises a non-bicyclic sugar moiety that includes a 2'-MOE. [Section 66] 59. The compound of claims 1-51 or 57-58, wherein each nucleoside of the second modified oligonucleotide comprises a non-bicyclic sugar moiety that includes 2'-OMe. [Section 67] 60. The compound of any of claims 1-51 or claim 59, wherein each nucleoside of the second modified oligonucleotide comprises a sugar surrogate selected from morpholino, PNA, F-HNA, THP, or modified THP. [Section 68] 68. The compound of any one of claims 1 to 67, wherein the second modified oligonucleotide consists of 6 to 10 linked nucleosides. [Section 69] 68. The compound of any one of claims 1 to 67, wherein the second modified oligonucleotide consists of 7 to 10 linked nucleosides. [Section 70] 68. The compound of any one of claims 1 to 67, wherein the second modified oligonucleotide consists of 8 to 10 linked nucleosides. [Section 71] 68. The compound of any one of claims 1 to 67, wherein the second modified oligonucleotide consists of 8 to 9 linked nucleosides. [Section 72] 68. The compound of any one of claims 1 to 67, wherein the second modified oligonucleotide consists of 7 to 9 linked nucleosides. [Section 73] 62. The compound of any one of claims 1 to 61, wherein the second modified oligonucleotide consists of 8 linked nucleosides. [Section 74] 64. The compound of any of claims 1-61 or 63, wherein the second modified oligonucleotide consists of 9 linked nucleosides. [Section 75] 68. The compound of any one of claims 1 to 67, wherein the second modified oligonucleotide comprises at least one modified internucleoside linkage. [Section 76] 76. The compound of any one of claims 1 to 75, wherein each internucleoside linkage of the second modified oligonucleotide is either an unmodified phosphodiester internucleoside linkage or a phosphorothioate internucleoside linkage. [Section 77] 77. The compound of claim 75 or 76, wherein each nucleoside linkage of said second modified oligonucleotide is a phosphorothioate internucleoside linkage. [Section 78] 77. The compound of claim 76, wherein each nucleoside linkage of said second modified oligonucleotide is an unmodified phosphodiester internucleoside linkage. [Section 79] 79. The compound of any of claims 1-78, wherein the first modified oligonucleotide or the second modified oligonucleotide comprises at least one modified nucleobase. [Section 80] 80. The compound of claim 79, wherein said modified nucleobase is 5'-Me cytosine. [Section 81] 80. The compound of Claim 79, wherein each nucleobase of each modified oligonucleotide is an unmodified nucleobase or a 5'-Me cytosine. [Section 82] 82. The compound of any one of claims 1 to 81, wherein the 3'-most nucleobase of the second modified oligonucleotide is complementary to the 5'-most nucleobase of the first modified oligonucleotide. [Section 83] 83. The compound of any one of claims 1 to 82, wherein the linking group is covalently attached to the first modified oligonucleotide. [Section 84] 83. The compound of any one of claims 1 to 82, wherein the linking group is covalently attached to the second modified oligonucleotide. [Section 85] 83. The compound of any one of claims 1 to 82, wherein the linking group is covalently attached to the 3' end of the first modified oligonucleotide. [Section 86] 83. The compound of any one of claims 1 to 82, wherein the linking group is covalently attached to the 5' end of the first modified oligonucleotide. [Section 87] 83. The compound of any one of claims 1 to 82, wherein the linking group is covalently attached to the 3' end of the second modified oligonucleotide. [Section 88] 83. The compound of any one of claims 1 to 82, wherein the linking group is covalently attached to the 5' end of the second modified oligonucleotide. [Section 89] 89. The compound of any one of claims 1 to 88, wherein the attachment group comprises a coupling linker. [Section 90] 90. The compound of any one of claims 1 to 89, wherein the linking group comprises a linking moiety. [Section 91] 91. The compound of any one of claims 1 to 90, wherein the binding group consists of a binding linker and a binding moiety. [Section 92] 82. The compound of any one of claims 1 to 81, wherein the binding moiety is a lipid. [Section 93] The binding moiety is C 16 82. The compound of any one of claims 1 to 81, comprising an alkyl. [Section 94] 82. The compound of any one of claims 1 to 81, wherein the binding moiety is cholesterol. [Section 95] 95. The compound of any one of claims 89 to 94, wherein the attachment linker is TCA. [Section 96] 95. The compound of any one of claims 89 to 94, wherein the attachment linker is TEG. [Section 97] 95. The compound of any one of claims 89 to 94, wherein the attachment linker is hexylamino. [Section 98] 98. The compound according to any one of claims 1 to 97, wherein the compound exists mainly as a double chain at 57°C or below. [Section 99] 98. The compound according to any one of claims 1 to 97, wherein the compound exists mainly as a double-stranded chain at 47°C or below. [Section 100] 98. The compound according to any one of claims 1 to 97, wherein the compound exists predominantly as a double-stranded chain at 37°C. [Section 101] 101. A pharmaceutical composition comprising a compound according to any one of claims 1 to 100 and a pharmacologically acceptable carrier or diluent. [Section 102] 101. A pharmaceutical composition comprising a compound according to any one of claims 1 to 100 and a pharmacologically acceptable carrier or diluent. [Section 103] 103. A method comprising administering to an animal a compound or pharmaceutical composition according to any one of claims 1 to 102. [Section 104] The method according to claim 103, wherein the compound or pharmaceutical composition according to any one of claims 1 to 94 is administered systemically. [Section 105] A method for treating a disease associated with an extrahepatic nucleic acid target, comprising administering a therapeutically effective amount of a compound or pharmaceutical composition according to any one of claims 1 to 103 to an individual suffering from or at risk of developing a disease associated with the extrahepatic nucleic acid target, thereby treating the disease associated with the extrahepatic nucleic acid target. [Section 106] 106. The method of claim 105, wherein the extrahepatic nucleic acid target is a muscle target. [Section 107] 106. The method of claim 105, wherein the extrahepatic nucleic acid target is DMPK. [Section 108] 106. The method of claim 105, wherein the extrahepatic nucleic acid target is a CNS target. [Section 109] The method according to any one of claims 105 to 108, wherein the administration is systemic administration. [Section 110] 106. The method of claim 105, wherein the administration is intrathecal administration. [Section 111] The method according to any one of claims 105 to 108, wherein the administration is parenteral administration. [Example]

[0260] The following examples illustrate, but do not limit, specific embodiments of the present disclosure. Furthermore, when specific embodiments are described, the inventors intend that these specific embodiments be generally applicable. For example, the disclosure of an oligonucleotide having a specific motif provides rational support for other oligonucleotides having the same or similar motif. Also, for example, if a specific high-affinity modification appears at a specific position, other high-affinity modifications at the same position are considered appropriate unless otherwise specified.

[0261] Example 1: Synthesis of cholesterol-linked oligonucleotides The modified oligonucleotides selected are listed in the table below. The modified oligonucleotides were synthesized by standard solid phase oligonucleotide synthesis methods well known in the art. The modified oligonucleotides were either 100% complementary (antisense) to the complementary strand (SEQ ID NO: 1) of the DMPK gene, i.e., GENBANK No. NT_011109.15 excised at 18540696_18555106, or 100% complementary (antisense) to the complementary strand (SEQ ID NO: 1) of the DMPK gene, i.e., GENBANK No. NT_011109.15 excised at 18540696_18555106. All oligonucleotides share 100% sequence identity with their complementary strands (sense), except for 819733, which contains a TCA linker on the 5' end prior to the portion of the oligonucleotide that is 100% complementary to the complementary strand of GENBANK No. NT_011109.15 excised by 18540696_18555106. Duplexes were formed by annealing the first and second purified single-stranded oligonucleotides together to form a duplex.

[0262] CholTEG (written from 5' to 3') and TEGChol (written from 3' to 5') have this structure. [ka] Refers to...

[0263] 3TEGChol (written from 5' to 3') and TEG3Chol (written from 3' to 5') have this structure. [ka] Refers to... [Table 1] CholTEG and 3TEGChol represent the cholesterol subunits listed above. In the subscripts in the table above, "s" represents a phosphorothioate internucleoside linkage, "o" represents a phosphate internucleoside linkage, "m" represents a 2'-O-methylnucleoside, "r" represents a ribose nucleoside, "d" represents a 2'-deoxynucleoside, and "k" represents a 2'-constrained ethyl nucleoside. In the superscripts, the "m" before the C represents 5-methylcytosine. [Table 2]

[0264] Example 2: Activity of modified oligonucleotides and hemiduplexes directed against mouse muscle DMPK treatment The modified oligonucleotides described above were tested in mice to evaluate the activity and tolerability of the oligonucleotides. Wild-type BALB / c mice were administered single oligonucleotides or duplexes intravenously at 5 mg / kg / week, 6 mg / kg / week, 10 mg / kg / week, or 20 mg / kg / week, as shown in the table below, once weekly for 4 weeks. Each treatment group consisted of four mice. Four mice in one group received PBS as a negative control. 48 hours after the final dose, animals were sacrificed. Quadriceps muscles were harvested from each animal and RT-PCR was performed. Results were normalized to GADPH and presented relative to the PBS control. "Not tolerated" means that the mouse was removed from the study after physical observation for one or more indicators of toxicity. The half-duplex compounds demonstrated improved tolerability compared to the single-stranded analogs and increased activity and tolerability compared to the hairpin analogs. The half-duplex compounds also demonstrated increased activity in muscle tissue compared to the full duplex analogs. [Table 3] [Table 4]

[0265] Example 3: Synthesis of cholesterol-linked oligonucleotides The selected modified oligonucleotides are listed in the table below and were synthesized according to the methods described in Example 1. [Table 5]

[0266] In the subscripts in the table above, "s" represents a phosphorothioate internucleoside linkage, "o" represents a phosphate internucleoside linkage, "m" represents a 2'-O-methylnucleoside, "r" represents a ribose nucleoside, "d" represents a 2'-deoxynucleoside, and "k" represents a 2'-constrained ethyl nucleoside. In the superscripts, the "m" before a C represents 5-methylcytosine.

[0267] Example 4: Acute Tolerance of DMPK-Directed Modified Oligonucleotides and Hemiduplexes treatment The above modified oligonucleotides were tested in mice to evaluate the tolerability of the oligonucleotides. Wild-type BALB / c mice were administered single oligonucleotides or duplexes at 24 mg / kg by intravenous injection as shown in the table below. Each treatment group consisted of four mice. Four mice in one group were administered PBS as a negative control. One hour after the 24 mg / kg injection, the animals were sacrificed. Animals were also observed after the 24 mg / kg injection. "Lethargic, rolling" means that after physical observation, the mice were significantly less active than the control group and showed poor balance, including an inability to right themselves and repeated rolling. The half-duplex compounds showed improved tolerability compared to the single-chain analogs. The half-duplex compounds also showed improved tolerability compared to the full duplex analogs. [Table 6]

[0268] Example 5: Synthesis of cholesterol-linked oligonucleotides The selected modified oligonucleotides are listed in the table below and were synthesized according to the methods described in Example 1. [Table 7]

[0269] In the subscripts in the table above, "s" represents a phosphorothioate internucleoside linkage, "o" represents a phosphate internucleoside linkage, "m" represents a 2'-O-methyl nucleoside, "r" represents a ribose nucleoside, "d" represents a 2'-deoxynucleoside, and "k" represents a 2'-constrained ethyl nucleoside. In the superscripts, the "m" before the C represents 5-methylcytosine. "CholTEG" has the meaning given above.

[0270] Example 6: Activity of systemically administered modified oligonucleotides and hemiduplexes directed against Malat-1 The modified oligonucleotides described above were tested in mice to evaluate the activity of the oligonucleotides in various tissues. As described above, compound 556007 is a single-stranded oligonucleotide complementary to the Malat-1 transcript. Compound 556007 is complementary to the complementary strand (SEQ ID NO: 19) of the Malat-1 gene, i.e., GENBANK number NT_082868.4 excised at 2689000_2699000. Compounds 1166384, 1166383, 1188901, 1194726, 1194723, 1194722, and 1166379 are complementary to compound 556007. Compound 556007 and compound The antibody was annealed with each of the following antibodies: 1166384, 1166383, 1188901, 1194726, 1194723, 1194722, and 1166379 to form the half-duplexes listed in the table below. These half-duplexes were then administered to mice.

[0271] treatment Wild-type BALB / c mice received a single intravenous injection of the half-duplex at either 7 mg / kg / week or 50 mg / kg / week once a week for 4 weeks, as indicated in the table below. Each treatment group consisted of four mice. Four mice in one group received PBS as a negative control. 72 hours after the final dose, the animals were sacrificed. Tissues from the cortex, spinal cord, striatum, cerebellum, liver, retina, kidney, and quadriceps muscle were collected from each animal and subjected to RT-PCR. Results were normalized to GADPH and are shown relative to the PBS control. The half-duplex compound demonstrated improved activity in the CNS after systemic administration compared to the single-stranded oligonucleotide alone. [Table 8] [Table 9]

Claims

1. A compound comprising a first oligomeric compound and a second oligomeric compound, the first oligomeric compound consists of a first modified oligonucleotide, or consists of a first modified oligonucleotide and a linking group and / or a terminal group, the first modified oligonucleotide consisting of 16 to 20 linked nucleosides and having a nucleobase sequence complementary to the nucleobase sequence of the second oligomeric compound and a nucleic acid target; the second oligomeric compound consists of a second modified oligonucleotide or consists of a second modified oligonucleotide and a linking group and / or a terminal group, the second modified oligonucleotide consisting of 8 to 12 linked nucleosides; the first modified oligonucleotide and the second modified oligonucleotide comprise at least one modified nucleoside comprising a modified sugar moiety; The at least one modified nucleoside comprising the modified sugar moiety is (a) a bicyclic sugar moiety, wherein said bicyclic sugar moiety has a 2'-4' bridge, said 2'-4' bridge being -O-CH ２ -, and -O-CH(CH ３ )- or the 2'-4' bridge is selected from cEt or LNA; and / or (b) a modified non-bicyclic sugar moiety, wherein the modified non-bicyclic sugar moiety comprises 2'-MOE or 2'-OMe; and / or (c) a sugar surrogate, wherein said sugar surrogate is selected from a morpholino, a PNA, an F-HNA, a THP, or a modified THP; Including; the nucleobase sequence of said first modified oligonucleotide comprises a region that is 100% complementary to said target nucleic acid; the region of 100% complementarity is 10 to 18 nucleobases in length, or 18 to 20 nucleobases in length; the nucleobase sequence of said first modified oligonucleotide comprises a region that is 100% complementary to said second modified oligonucleotide; the second modified oligonucleotide is 100% complementary to the first modified oligonucleotide over the length of the second modified oligonucleotide, or the nucleobase sequence of the first modified oligonucleotide is such that when the first and second oligomeric compounds are aligned, no nucleobase of the first modified oligonucleotide is complementary to the corresponding nucleobase of the second modified oligonucleotide; the first modified oligonucleotide comprises at least five consecutive linked 2'-deoxynucleosides; The attachment group is specified as consisting of a coupling linker and a binding moiety, wherein the binding moiety is selected from a cholesterol moiety, cholic acid, thioether, thiocholesterol, an aliphatic chain, a phospholipid, a polyamine or polyethylene glycol chain, an adamantane acetic acid, a palmityl moiety, an octadecylamine moiety or a hexylamino-carbonyl-oxycholesterol moiety, a tocopherol group, a GalNAc cluster, an intercalator, a reporter molecule, a polyamine, a polyamide, a peptide, a carbohydrate, a vitamin moiety, polyethylene glycol, a thioether, a polyether, cholesterol, thiocholesterol, a cholic acid moiety, a folate, a lipid, a phospholipid, biotin, a phenazine, a phenanthridine, an anthraquinone, an adamantane, an acridine, a fluorescein, a rhodamine, a coumarin, a fluorophore, and a dye. The compound.

2. 2. The compound of claim 1, wherein the first modified oligonucleotide has a nucleobase sequence that is at least 80%, at least 90%, or 100% complementary to the nucleobase sequence of the target nucleic acid when measured across the entire nucleobase sequence of the first modified oligonucleotide.

3. the first modified oligonucleotide has a gapmer comprising a 5'-region, a central region, and a 3'-region; wherein the sugar moieties of the nucleosides of the 3'-most nucleoside of the 5'-region and the 5'-most nucleoside of the 3'-region are different from those of the adjacent nucleosides of the central region; The compound according to any one of claims 1 to 2.

4. (a) the first modified oligonucleotide comprises: a 5'-region consisting of 1 to 5 linked 5'-nucleosides; a central region consisting of 6 to 10 linked central region nucleosides; and a 3'-region consisting of 1 to 5 linked 3'-nucleosides wherein each of the 5'-region nucleosides and each of the 3'-regions comprises a modified sugar moiety, and each of the central region nucleosides comprises an unmodified DNA sugar moiety. or, (b) the first modified oligonucleotide comprises: a 5'-region consisting of 5 linked 5'-nucleosides; a central region consisting of 10 linked central region nucleosides, and a 3'-region consisting of five linked 3'-nucleosides wherein each of the 5'-region nucleosides and each of the 3'-regions comprises a modified sugar moiety, and each of the central region nucleosides comprises an unmodified DNA sugar moiety. or, (c) the first modified oligonucleotide comprises: a 5'-region consisting of three linked 5'-nucleosides; a central region consisting of 10 linked central region nucleosides, and a 3'-region consisting of three linked 3'-nucleosides wherein each of the 5'-region nucleosides and each of the 3'-regions comprises a modified sugar moiety, and each of the central region nucleosides comprises an unmodified DNA sugar moiety. The compound according to any one of claims 1 to 3.

5. The compound of any one of claims 1 to 3, wherein the first modified oligonucleotide consists of 16 to 18, or 16, or 20 linked nucleosides.

6. 6. The compound of any one of claims 1 to 5, wherein the second modified oligonucleotide is 100% complementary to the first modified oligonucleotide over the length of the second modified oligonucleotide.

7. the first modified oligonucleotide and / or the second modified oligonucleotide comprises at least one modified nucleoside comprising a cEt bicyclic sugar moiety; and / or the first modified oligonucleotide comprises at least one modified nucleoside, including a 2'-MOE modified nucleoside; The compound according to any one of claims 1 to 6.

8. (a) the second modified oligonucleotide comprises: a 5'-region consisting of 2 to 4 linked 5'-nucleosides; a central region consisting of 2 to 4 linked central region nucleosides, and a 3'-region consisting of 2 to 4 linked 3'-nucleosides wherein each of the 5'-region nucleosides and each of the 3'-regions comprises a modified sugar moiety, and each of the central region nucleosides comprises an unmodified DNA sugar moiety. or, (b) the second modified oligonucleotide comprises: a 5'-region consisting of two linked 5'-nucleosides, a central region consisting of four linked central region nucleosides, and a 3'-region consisting of two linked 3'-nucleosides wherein each of the 5'-region nucleosides and each of the 3'-regions comprises a modified sugar moiety, and each of the central region nucleosides comprises an unmodified DNA sugar moiety. or, (c) the second modified oligonucleotide comprises: a 5'-region consisting of four linked 5'-nucleosides; a central region consisting of two linked central region nucleosides, and a 3'-region consisting of three linked 3'-nucleosides wherein each of the 5'-region nucleosides and each of the 3'-regions comprises a modified sugar moiety, and each of the central region nucleosides comprises an unmodified DNA sugar moiety. or, (d) the second modified oligonucleotide comprises: a 5'-region consisting of three linked 5'-nucleosides; a central region consisting of 5 linked central region nucleosides, and a 3'-region consisting of three linked 3'-nucleosides wherein each of the 5'-region nucleosides and each of the 3'-region nucleosides comprises a modified sugar moiety, and each of the central region nucleosides comprises an unmodified RNA sugar moiety. The compound according to any one of claims 1 to 7.

9. Each nucleoside of the second modified oligonucleotide is (a) comprises a non-bicyclic sugar moiety that includes 2'-MOE; or (b) comprises a non-bicyclic sugar moiety that includes 2'-OMe; or (c) comprising a sugar surrogate selected from morpholino, PNA, F-HNA, THP, or modified THP; The compound according to any one of claims 1 to 8.

10. The compound of any one of claims 1 to 9, wherein the second modified oligonucleotide consists of 8 to 10, 8 to 9, 7 to 9, 8 or 9 linked nucleosides.

11. The compound of any one of claims 1 to 9, wherein the first modified oligonucleotide and / or the second modified oligonucleotide comprises at least one modified internucleoside linkage.

12. (a) each internucleoside linkage of said first modified oligonucleotide is a modified internucleoside linkage, and / or (b) at least one internucleoside linkage of said first oligonucleotide is a phosphorothioate internucleoside linkage, and / or (c) the first modified oligonucleotide comprises at least one unmodified phosphodiester internucleoside linkage; The compound according to any one of claims 1 to 11.

13. Each internucleoside linkage of the first modified oligonucleotide and / or the second modified oligonucleotide is (a) either unmodified phosphodiester or phosphorothioate internucleoside linkages; and / or (b) phosphorothioate internucleoside linkages; The compound according to any one of claims 1 to 12.

14. 14. The compound of claim 13, wherein each internucleoside linkage of the second modified oligonucleotide is an unmodified phosphodiester internucleoside linkage.

15. The compound of any one of claims 1 to 14, wherein the first modified oligonucleotide or the second modified oligonucleotide comprises at least one modified nucleobase.

16. 16. The compound of claim 15, wherein the modified nucleobase is a 5'-Me cytosine and each nucleobase of each modified oligonucleotide is an unmodified nucleobase or a 5'-Me cytosine.

17. 17. The compound of any one of claims 1 to 16, wherein the 3'-most nucleobase of the second modified oligonucleotide is complementary to the 5'-most nucleobase of the first modified oligonucleotide.

18. 18. A compound according to any one of claims 1 to 17, comprising a linking group, the linking group is covalently attached to the first modified oligonucleotide; or the linking group is covalently attached to the second modified oligonucleotide; or the linking group is covalently attached to the 3' end of the first modified oligonucleotide; or the linking group is covalently attached to the 5' end of the first modified oligonucleotide; or the linking group is covalently attached to the 3' end of the second modified oligonucleotide; or the linking group is covalently attached to the 5' end of the second modified oligonucleotide; The compound.

19. the binding moiety is a lipid, or The binding moiety is C １６ containing alkyl, or the binding moiety is cholesterol; The compound according to any one of claims 1 to 18.

20. the attachment linker is a TCA, or the attachment linker is TEG, or the attachment linker is hexylamino; The compound according to any one of claims 1 to 19.

21. the compound exists as a duplex at temperatures below 57°C; or the compound exists as a duplex at temperatures below 47°C; or The compound exists as a duplex at 37°C. The compound according to any one of claims 1 to 20.

22. A pharmaceutical composition comprising a compound according to any one of claims 1 to 21 and a pharmacologically acceptable carrier or diluent.

23. 23. The pharmaceutical composition of claim 22, for administration to an animal.

24. 24. The pharmaceutical composition of claim 23, which is administered systemically.

25. A pharmaceutical composition according to any one of claims 22 to 24 for treating a disease associated with an extrahepatic nucleic acid target, wherein the pharmaceutical composition is administered to an individual suffering from or at risk of developing a disease associated with the extrahepatic nucleic acid target.

26. The extrahepatic nucleic acid target is a muscle target, or the extrahepatic nucleic acid target is DMPK; or The extrahepatic nucleic acid target is a CNS target.

26. The pharmaceutical composition of claim 25.

27. The administration is systemic, or The administration is intrathecal administration, or The administration is parenteral.

27. The pharmaceutical composition of claim 25 or 26.

Images